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EXPRESSION  
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M.Sc. in Molecular Biology and Genetics 
Advisor: Asst. Prof. Özlen KONU 
August 2009, 152 pages 
 
Breast cancer, highly heterogeneous in nature, has been classified into multiple molecular 
subtypes based on hormone receptor status and also possess variable genetic and environmental 
etiologies. Prognosis and therapy of breast cancer depends on the presence or absence of these 
molecular markers. Nicotine, the major psychoactive addictive component in tobacco smoke, 
has been associated with multiple cancers because of its ability to increase cell proliferation, 
migration, and angiogenesis, and to decrease apoptosis. Nicotine binds to cholinergic receptors 
made up of multiple subunits, one of which, the alpha 5 (CHRNA5) whose polymorphisms have 
recently been implicated in nicotine addiction and lung cancer as functional. Microarray 
datasets provide genomic and functional information on the whole transcriptome when exposed 
to a certain treatment or under different pathological conditions allowing for molecular 
classification. The association between nicotine use and breast cancer has been controversial 
and to our knowledge no high-throughput expression profiling of breast cancer cells exposed to 
nicotine exists in the literature. In the present study, we determined that 1 uM nicotine affects 
cell proliferation in MCF7 cells measured by MTT assay only under serum starvation (0.1% 
Serum) condition at days 5 or 7 but not earlier. Similarly, effects on the protein levels of 
selected molecular markers with roles in proliferation and/or apoptosis, i.e., CyclinE, bcl-xl, and 
p53 were affected under serum starved conditions in more pronounced ways. Effects of nicotine 
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at the transcriptome level were studied in MCF7 cells when exposed to 1uM Nicotine using 
Affymetrix Human HGU133 plus 2 arrays under the 10% serum levels. Our findings indicated 
that nicotine affects multiple pathways including MAPK, focal adhesion, and apoptosis 
although the magnitude of changes was mild. Preliminary analyses performed under serum-
starvation indicated that starvation resulted in drastic changes in MCF7 transcriptome, some of 
which can be reversed, by 1uM nicotine. CHRNA5 expression was highly modulated by serum 
levels. Multiple microarray datasets on breast cancer cell lines and primary tumors in GEO were 
re-analyzed to assess the dependency of CHRNA5 expression on estrogen. Our findings were: 
1) CHRNA5 expression increased in the presence of estrogen in a dose- and time-dependent 
fashion; 2) CHRNA5 was found to be a likely secondary target of estrogen; 3) CHRNA5 
expression was higher in ER negative and/or Grade 3 breast cancer patients, implicating 
CHRNA5 with prognosis; 4) DNA replication and cell cycle genes seemed to be highly 
correlated with CHRNA5 expression; 5) the coexpressed genes could predict ER and Grade 
status of primary tumors with high accuracies. In conclusion, cholinergic signaling as 
modulated by nicotine through acetylcholine receptors might have a role in breast cancer 
etiology. CHRNA5 represents a novel candidate for breast cancer diagnostic and prognostic 
studies. 
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ÖZET 
MCF7 MEME KANSER HÜCRE HATTINDA NİKOTİNDEN ETKİLENMİŞ GEN 
İFADE PROFİLLERİ VE CHRNA5 İFADESİNDE ESTROJENİN ROLÜ 
 
Rümeysa BIYIK 
 
Master Tezi, Moleküler Biyoloji ve Genetik Bölümü 
Tez Yöneticisi: Yrd. Doç. Özlen Konu 
Ağustos, 2009 152 sayfa 
 
Heterojen bir yapısı olan meme kanseri bir çok moleküler alttipe ayrılmış olup birbirinden 
farklı genetik ve çevresel nedenlerden kaynaklanabilir. Meme kanserinin prognozu ve tedavisi 
sözü edilen moleküler belirteçlerin varlığına bağlıdır. Tütünün en belirgin fizyoaktif ve bağlılık 
yapıcı maddesi olan nikotin, hücre bölünmesi, hareketi ve anjiogenezi arttırması ve apoptozu 
önlemesi dolayısı ile birden fazla kanser ile ilintilendirilmiştir. Nikotin bir çok altüniteden 
oluşan kolinerjik reseptörlere bağlanır; bunlardan biri olan alfa 5 (CHRNA5) fonksiyonel 
polimorfizmleri dolayısı ile nikotin bağımlılığı ve akciğer kanseri ile ilintilendirilmiştir. 
Mikrodizin verisetleri genomik ve işlevsel bilgiyi bir ajana maruz kalma ya da farklı patolojik 
durumlarda tüm transkriptom düzeyinde moleküler bir gruplamaya olanak verecek şekilde 
sağlarlar. Nikotin kullanımı ve meme kanseri arasındaki ilişki tartışmalı olup bilgimiz dahilinde 
nikotine maruz kalan hücrelerde şimdiye kadar yüksek ölçekli ifade profillemesi yapılmamıştır. 
Bu çalışmada, MTT assay ile ölçüldüğü üzere, 1 uM nikotin, 0.1% serum açlığına maruz kalan 
MCF7 hücrelerinin bölünmesini 5. ve 7. günlerden itibaren etkilemiştir. Benzer bir şekilde, 
bölünme ve apoptozda görevli moleküler belirteçlerin, örneğin, CyclinE, bcl-xl, p53, protein 
miktarları da serum açlığı halinde daha belirgin bir şekilde gözlenmiştir. 10% serum altında 
büyütülen MCF7 hücrelerinin 1 uM nicotine verdikleri yanıt Affymetrix İnsan HGU133 plus 2 
mikrodizinleri kullanarak çalışılmıştır. Bulgularımız, nikotinin MAPK, apoptoziz ve fokal 
adhezyon gibi sinyal yolaklarını etkilediğini göstermekle birlikte değişikliklerin miktarı 
düşüktür. Serum açlığı uygulanarak yapılan ön çalışmalar serum eksikliğinin ifade profilinde 
oldukça etkili olduğunu gösterdi; bu değişikliklerin bazıları 1 uM nikotin ile geri çevrilebilir 
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görünmektedir. CHRNA5 ifadesi serum seviyesinden etkilenmiştir. CHRNA5 ifadesinin 
estrogene bağımlığını test etmek üzere GEO veritabanından çok sayıda meme kanser hücre hattı 
ve primer tümör verisi incelenmiştir. Bulgularımız şöyle özetlenebilir: 1) CHRNA5 ifadesi 
estrojenin varlığında doza ve zamana bağlı olarak yükselmiştir; 2) CHRNA5 estrojenin ikincil 
bir hedefi olabilir; 3) CHRNA5 ifadesi ER negatif ve Grade 3 hastalarında daha yüksek olup bu 
durum CHRNA5’i prognoz ile ilişkilendirir; 4) DNA replikasyon ve hücre döngüsü genleri 
CHRNA5 ifadesi ile yüksek derecede korelasyon gösterir; 5) CHRNA5 ile birlikte ifade olan 
genler primer tümörlerin ER ve Grade statüsünü yüksek bir doğrulukla tahmin edebilirler. 
Sonuç olarak, nikotinin asetilkolin reseptörleri yoluyla değiştirebildiği kolinerjik sinyaller 
meme kanser etiolojisinde yer taşıyabilir. CHRNA5 meme kanser prognostik ve diagnostik 
çalışmalarında yeni bir hedef teşkil etmektedir. 
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CHAPTER 1: INTRODUCTION 
 
1.1. Cholinergic Signaling 
1.1.1. Tobacco use, cancer and nicotine: 
 
Smoking is one of the leading causes of cancer–related deaths worldwide. Recent 
studies suggest that 25% of all cancers in men and 4% in women are related to smoking 
(Stewart and Kleihues 2003). Studies carried out in Europe, Japan and North America also 
demonstrate that 91% of all lung cancers in men and 69% in women are related to cigarette 
smoking (Stewart and Kleihues 2003). In addition, smoking is one of the main risks for the 
oesophagus, larynx, oral cavity and stomach cancers for males and females (Sasco, Secretan 
et al. 2004). 
 4000 different chemicals are found in cigarette smoke and more than 60 are identified 
as carcinogens according to the study of International Agency for Research on Cancer (IARC 
2004). Nicotine, first isolated from the tobacco plant Nicotiana tabacum (Fig. 1.1.1) by 
German chemists Posselt and Riemannin in 1828, is the principal psychoactive and addictive 
component in tobacco; and it is highly addictive (Catassi, Servent et al. 2008). Consequently, 
smokers are exposed to a diverse array of carcinogens and other bioactive compounds in 
tobacco, making tobacco use the leading cause of premature deaths in developed countries 
(Peto and Doll 1992). The common idea is that the carcinogens in cigarette smoke are 
converted into the bulky compounds and these compounds react with DNA, thereby leading 
to DNA adducts and genetic alterations in cancer (Catassi, Servent et al. 2008). However, 
recent studies challenge this conception and suggest that components such as nicotine act as 
signaling molecules modulating cellular homeostasis (Dasgupta and Chellappan 2006; 
Dasgupta, Kinkade et al. 2006; Dasgupta, Rastogi et al. 2006). On the other hand, multiple 
studies about the therapeutic effects of nicotine for Parkinson’s disease, Alzheimer’s disease, 
and ulcerative colitis are present (Jani and Regueiro 2002; Quik and Kulak 2002; Sabbagh, 
Lukas et al. 2002). 
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Figure 1.1.1. Structure of nicotine. A) Tobacco plant. B) Chemical structure of nicotine. 
Modified from (Catassi, Servent et al. 2008). 
 
Nicotine absorption takes place through the oral cavity, skin, lung, urinary bladder, and 
gastrointestinal tract (Schevelbein, Eberhardt et al. 1973). Nicotine levels in blood increase 
rapidly during the completion of cigarette smoking because nicotine is readily absorbed once 
it reaches the lungs (Catassi, Servent et al. 2008). Other routes for absorption include skin 
and stomach; skin allows for diffusion at different rates while stomach is acidic thus does not 
enable rapid absorption. However, nicotine is well absorbed in the small intestine due to the 
higher pH and a large surface area (Hukkanen, Jacob et al. 2005). 
 
1.1.2. The structure and function of nicotinic acetylcholine receptors (nAChRs): 
 
Nicotinic acetylcholine receptors (nAChR/CHRNs) are ion channels located on the 
plasma membrane of neuronal and non-neuronal cells and tissues (Sobel and Changeux 1977; 
Lindstrom, Anand et al. 1996; Lukas, Changeux et al. 1999; Sharma and Vijayaraghavan 
2002; Gotti and Clementi 2004; Wessler and Kirkpatrick 2008). 10α subunits (α1-α10) and 
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4β subunits (β1-β4) are identified (Lukas, Changeux et al. 1999). A functional receptor 
complex consists of homo- or heteropentamer of α1–α10 and β1–β4 subunits that are 
arranged symmetrically around an axis perpendicular to the membrane. The composition and 
stoichiometry of the subunits determine the cation selectivity, desensitization kinetics and 
spatial distribution (Catassi, Servent et al. 2008). Although nAChRs were first identified in 
the neuronal system, recent studies indicate the presence of nAChRs in a variety of non-
neuronal cells (Egleton, Brown et al. 2008). 
All nAChR subunits possess a large extracellular domain, four transmembrane regions 
(M1–M4) with an α-helix structure, a large cytoplasmic domain between M3 and M4 and 
ﬁnally a short extracellular C-terminal tail (Fig. 1.1.2). The loops present on the extracellular 
regions of nAChR maintain the ACh binding site while transmembrane segment of M2 
contributes to the lining of the pore (Corringer, Le Novere et al. 2000). The structural 
coupling between these domains plays key roles in signal transduction between the natural 
ligand acetylcholine (Ach) binding and the ion channel gating, the depolarization of the post-
synaptic membrane, and the propagation of an action potential. Aside from the 
agonistic/antagonist binding site, diverse interaction sites are present on nAChRs for both 
non-competitive inhibitors and allosteric modulators (Hogg, Buisson et al. 2005). 
 
Figure 1.1.2. Schematic organization of a single subunit and the pentameric nAChRs (Russo, 
Catassi et al. 2006). 
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In recent years, crystallographic structure studies about the extracellular domain of 
nAChRs, electronic microscopy images and several biochemical studies on the ligand 
binding sites have increased the understanding of the interactions of different nAChRs with 
diverse ligands as well as the molecular level of these interactions and the primary motion 
leading to the receptor activation. These findings have become important for the drug-design 
related to the therapy of neurological disorders such as Alzheimer’s or Parkinson’s disease, 
schizophrenia, anxiety, pain or epileptic disorders (Newhouse, Singh et al. 2004; Singh, 
Potter et al. 2004). 
Acetylcholine is the physiological agonist for all nAChRs (Wessler and Kirkpatrick 
2008). Rapid conformational alterations from resting basal state to active or open–channel 
state may occur in nAChRs, similar to allosteric receptors. Long-exposure to acetylcholine 
leads to stabilization of the receptor in a closed desensitized state (Corringer, Le Novere et al. 
2000). Similar to acetylcholine, nicotine binds as an agonist to α subunits of nAChRs. These 
interactions lead to conformational changes in the receptor and open the gate on the 
intracellular side of the ion channel in the plasma membrane. Consequently, ions flow into 
the cells (Lindstrom, Anand et al. 1996). Increased level of cations in the cells leads to 
membrane depolarization via decreasing the negative charges on the intracellular side of the 
plasma membrane. Then, membrane depolarization opens gates on the intracellular side of 
the plasma membrane of voltage-activated Ca++ channels, thereby resulting in an additional 
influx of Ca++. Finally, all these events activate many diverse responses such as the release 
of neurotransmitters, growth, angiogenic and neurotrophic factors, and stimulation of 
different signaling cascades involved in the regulation of cell proliferation, apoptosis, 
migration and differentiation (Kunzelmann 2005; Kunzelmann, Sun et al. 2005; Roderick and 
Cook 2008). 
α7nAChR and α4β2nAChRs are the best studied receptors with respect to the 
biological effects of nicotine; and they are found most abundantly in the mammalian brain. 
Although prolonged exposure to agonists leads to down-regulation of other types of cellular 
receptors, prolonged nicotine exposure upregulates the expression of nAChRs (Kunzelmann 
2005). Like acetylcholine, nicotine interacts with higher affinity with the heteromeric 
nAChRs, particularly the α4β2nAChR, rather than with the α7nAChR7 (Barik and 
5 
 
Wonnacott 2006). While the chronic exposure to nicotine desensitizes α4β2nAChRs the 
sensitivity of α7nAChR does not change (Kawai and Berg 2001). Therefore, increased 
α7nAChR activity might be seen in smokers while α4β2nAChR may not be functional. Since 
desensitization does not occur permanently, removal of nicotine re-establishes receptor 
activity. Thus, cell lines rather than samples from tumors or tissues from smokers are more 
frequently used for studying effects of chronic exposure on desensitized heteromeric nAChRs 
(Schuller 2009). 
α7nAChR and α4β2nAChRs stimulate various neurotransmitters which act on brain 
and also may play important roles in cancer (Fig. 1.1.3). Nicotine modulates the amount of 
dopamine whose activity is essential in cognition and memory. In addition, dopamine is 
known to induce the proliferation of cancer cells in the prostate and mammary gland (Lang, 
Drell et al. 2004). On the other hand, the α4β2nAChR stimulates the release of the 
neurotransmitter γ-aminobutyric acid (GABA) that has an inhibitory activity on the brain. 
Moreover, GABA functions as a tumor suppressor for adenocarcinoma of the lung, pancreas, 
breast and colon (Schuller, Al-Wadei et al. 2008). Glutamate, serotonin, the stress 
neurotransmitters adrenaline and noradrenaline, and the neuropeptide mammalian bombesin 
are also stimulated by the α7nAChRs (Jull, Plummer et al. 2001). Apart from neurological 
functions, these agents also promote the growth of different types of cancers either via 
activation of the intracellular signaling pathways or regulation of the release of EGF, VEGF, 
or arachidonic acid. On the other hand, α7nAChR regulates the cholinergic control of 
immune cells and anti-inflammatory actions of the cholinergic system (Schuller 2009). 
Among the CHRN subunits, CHRNA5-CHRNA3-CHRNB4 cluster that exhibits 
conserved synteny (Boulter, O'Shea-Greenfield et al. 1990; Eng, Kozak et al. 1991) has 
gained recent attention due to association of particularly the CHRNA5 subunit with nicotine 
dependency (Greenbaum, Kanyas et al. 2006) as well as lung cancer (Falvella, Galvan et al. 
2009; Wang, Cruchaga et al. 2009). 
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Figure 1.1.3. “The diverse functions of the homomeric α7 nAChR and of the heteromeric 
α4β2nAChRs” (Schuller 2009).  
 
1.1.3. CHRNA5 (Nicotinic acetylcholine receptor alpha 5) 
 
1.1.3.1. Function of CHRNA5: 
 
A functional CHRN receptor is an ion channel that can either be homomeric or 
heteromeric pentamer of a given set of subunits (Lukas, Changeux et al. 1999). Auxial 
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CHRNA5 can form funtional pentamers with α3β4, α3β2 (Conroy, Vernallis et al. 1992) or 
with α4β2 CHRNs (Ramirez-Latorre, Yu et al. 1996). The presence of CHRNA5 subunit in 
α3β4 or α3β2 receptors may lead to functional changes including increased Ca++ 
permeability and desensitization (Gerzanich, Wang et al. 1998). Similarly, CHRNA5 subunit 
forming a pentamer with α4β2, which is the most abundant CHNR in the brain, increases 
conductance of these receptors and leads to a higher rate of desensitization (Ramirez-Latorre, 
Yu et al. 1996). Interestingly, CHRNA5 knock-out mice show no anatomical abnormalities in 
brain or other tissues; and these mice have normal level of mRNAs encoding other nAChR 
subunits (Wang, Orr-Urtreger et al. 2002). On the other hand, CHRNA5 knockout mice 
become less sensitive to nicotine-induced seizures and more resistant to the nicotine-induced 
hypo-locomotion in speciﬁc mouse strains although these mice demonstrate unchanged 
epibatidine and α-bungarotoxin binding ability in the brain (Salas, Orr-Urtreger et al. 2003). 
The nicotinic acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in 
vivo (Salas, Orr-Urtreger et al. 2003). Another study implicates cholinergic signaling through 
CHRNA5 in modulation of the severity of colitis symptoms since CHRNA5 knockout mice 
exhibit severe experimental colitis when compared with wild type controls (Orr-Urtreger, 
Kedmi et al. 2005). 
 
1.1.3.2. Polymorphism studies of CHRNA5 in connection with nicotine 
dependence: 
 
Recent studies related to the nicotine dependence and lung cancer risks have focused on 
the cluster of CHRNA3-CHRNA5-CHRNB4. One of the first studies that revealed an 
association of single nucleotide polymorphisms (SNPs) in cholinergic receptors with 
smoking phenotypes in women was by Greenbaum et al. (Greenbaum, 2006 #65). The 
authors demonstrated that multiple SNPs from a set of cholinergic receptor subunits might be 
associated with smoking initiation, nicotine dependence, neuroticism, or novelty seeking 
behaviors, and in particular, implicated SNPs in CHRNA7 and CHRNA5 with the severity of 
nicotine dependence (Greenbaum, Kanyas et al. 2006). Rigbi et al. analyzed a set of 39 SNPs 
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in 11 different CHRN subunits on a group of female college students identifying CHRNA5 
along with others in association with response inhibition, selective-sustained attention. More 
recently small or large scale genome wide studies have taken over the scene to study 
cholinergic signaling component driven genomic associations in populations that vary in 
gender and ethnicity (Rigbi, Kanyas et al. 2008). A non-synonymous SNP of CHRNA5, i.e., 
rs16969968 (D398N), was first identified for being a significant risk variant in developing 
nicotine dependence upon exposure to smoking in a large scale yet focused genome-wide 
study (Saccone, Hinrichs et al. 2007). Later, Heitjan et al. also identified a SNP (rs871058) 
on CHRNA5, located near to the rs16969968, while screening for a pharmocogenetic marker 
in the clinical trial of bupropion versus placebo for smoking cessation (Heitjan, Guo et al. 
2008). Grucza et al. found that rs16969968 was associated with a protective effect in cocaine 
dependence while it was a risk variant in nicotine dependence (Grucza, Wang et al. 2008). 
SNPs of CHRNA3, CHRNA5, and CHRNB4 cluster also were associated with early age of 
the initiation of both alcohol and tobacco use in young adults of Caucasian and Hispanic 
origin (Schlaepfer, Hoft et al. 2008). 
A common haplotype in CHRNA5/CHRNA3 from a large scale study investigating 
6000 SNPs on close to 2000 genes was associated with predisposition to nicotine dependence 
based on the number of cigarettes smoked per day (Berrettini, Yuan et al. 2008). Stevens et 
al. compared heavy smokers with light smokers to find out two different groups in the 
CHRNA5-CHRNA3-CHRNB4 cluster related to heavy smoking while rs16969968 was 
found to be the most likely candidate for the polymorphism responsible for increased risk of 
heavy smoking (Stevens, Bierut et al. 2008). Caporaso et al. recently provided further 
evidence that intensity of smoking was associated with rs16969968 while Saccone et al. 
extended their studies and showed that CHRNA5-CHRNA3-CHRNB4 together with others 
were associated with initiation of nicotine dependence (Caporaso, Gu et al. 2009; Saccone, 
Saccone et al. 2009). Weiss et al. investigated the relationship between age dependent-
addiction and the CHRNA5-CHRNA3-CHRNB4 cluster in three different populations of 
European origins (Weiss, Baker et al. 2008). They showed that specific haplotypes in this 
cluster were significantly associated with severity of nicotine dependence in populations 
started smoking before 16 but not in those started after 16. Taken together, these studies 
9 
 
implicated the CHRNA5-CHRNA3-CHRNAB4, and especially CHRNA5 in establishment 
of smoking behavior and addiction while demonstrating a strong genetic component. 
 
 
1.1.3.3. Polymorphism and expression studies of CHRNA5 in regard to 
cancer 
 
Apart from these studies implicating the CHRNA3-CHRNA5-CHNRB4 cluster with 
smoking parameters and behaviors, independent studies mapped these loci on 15q25 in 
association with lung cancer (Amos, Wu et al. 2008; Hung, McKay et al. 2008; Thorgeirsson, 
Geller et al. 2008). 
According to Hung et al., rs16969968 was associated with the lung cancers but this 
association was independent of nicotine addiction (Hung, McKay et al. 2008). On the other 
hand, Amos et al. found out that variation at rs8034191 was associated with both lung cancer 
and smoking behavior (Amos, Wu et al. 2008). Evidently, CHRN variants were more directly 
related to the lung cancer than the other smoking related cancers since in non-smoking 
populations no significant risk was associated with renal and bladder cancers (Spitz, Amos et 
al. 2008).  
CHRNA5 strongly being implicated as a risk factor for lung cancer development also 
accelerated research on its functional attributes using different systems. Earlier studies 
focused on the antisense regulation of CHRNA5 and CHRNA3 since these two genes shared 
evolutionarily conserved overlapping 3’UTR sequences that might allow for 
CHRNA3/CHRNA5 duplex formation as shown in human neuroblastoma SY5Y cells (Solda, 
Boi et al. 2005). In support of such a potential regulation, a 30-fold increase in CHRNA5 
expression and a decrease in expression of CHRNA3 were found in a group of lung 
adenocarcinoma patients and controls from Italy (Falvella, Galvan et al. 2009). In addition, 
they found a direct relationship between mRNA expression and allelic composition implying 
D398N (rs16969968) SNP with a functional role in lung cancer (Falvella, Galvan et al. 
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2009). In another study, Wang et al. studied with rs16969968 and rs588765 SNPs and found 
that D398N amino acid variant in CHRNA5 (rs16969968) led to altered receptor function 
rather than the level of mRNA expression; and both rs16969968 and rs588765 were 
associated with the nicotine dependence and lung cancers (Wang, Cruchaga et al. 2009). 
Bierut et al. investigated the functional role of D398N variant in D398 or N398 transfected 
HEK293T cells. Accordingly, N398 variant demonstrated a lower response to nicotine than 
D398 nevertheless N398 did not affect the receptor expression (Bierut, Madden et al. 2007). 
The association of lung cancer risk variants in CHRNA3 and CHRNA5 with intensity of 
smoking and exposure to carcinogenic nitrosamine (NNK) in cigarettes in regard to nicotine 
metabolism also have been well established: carriers with a T variant of rs1051730 
(CHRNA3) and/or A variant of rs16969968 (CHRNA5) were exposed to higher NNK levels 
than noncarriers even if they smoked the same amount (Le Marchand, Derby et al. 2008).  
On the other hand, not many studies focused on the role of CHRNA5 expression in 
other cancer types. Among them, nicotine exposure to keratinocytes led to up-regulation of 
CHRNA5 via the PKC pathway while this up-regulation was transient and followed by 
CHRNA7 up-regulation. Since inclusion of CHRNA5 in α3β2 and α3β4 CHRNs increased 
the Ca++ permeability, this suggested that up-regulation of CHRNA5 expression may lead to 
the intracellular accumulation of Ca++ and up-regulation of CHRNA7 via of CaMKII and 
p38 MAPK pathway. This study further demonstrated that the normal differentiation pattern 
of kerotinocytes involved the sequential expression of cholinergic receptors with differential 
Ca+ permeability (Arredondo, Chernyavsky et al. 2008). In another study, Song et al. found 
that CHRNA5 expression was higher in tumor samples from squamous cell lung cancer 
(SCC) patients and higher CHRNA5 expression was associated with lesser differentiated 
state in SCC cell lines (Song, Sekhon et al. 2008). 
 
1.1.4. Effect of nicotine on cell proliferation: 
 
The proliferative activity of nicotine has been shown in various normal and cancer cells 
(Gotti and Clementi 2004; Schuller 2007). Conti-Fine et al. and Zeidler et al. demonstrate 
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that nicotine causes increase in level of growth factors such as BDNF, VEGF, HGF, VEGF-
C, TGF-β, PDGF and TGF-α as well as growth factor receptors such as VEGFR-2, PDGFR, 
HGFR and EGFR, thereby, promoting cell proliferation (Conti-Fine, Navaneetham et al. 
2000; Zeidler, Albermann et al. 2007). In addition, studies using selective antagonists such as 
α –bungarotoxin, hexamethonium and RNAi show that α7nAChR plays a key role in the 
proliferative activity of nicotine (Heeschen, Weis et al. 2002; Trombino, Cesario et al. 2004; 
Dasgupta, Rastogi et al. 2006). 
 
Figure 1.1.4. Schematic representation of the proliferative activity of nicotine via α7nAChR 
in cells. α-BT: α -bungarotoxin; Hex: hexamethonium (Egleton, Brown et al. 2008). 
 
Nicotine’s interaction with α7-nAChR promotes the formation of an oligomeric 
complex, including β-arrestin, Src and α7-nAChR, which in turn leads to the activation of Src 
(Fig. 1.1.4). Activated Src initiates the MAP kinase pathway and induces Raf-1 interaction 
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with RB. Then, E2F, Rb and Raf-1 come together and make complexes to bind the 
proliferative promoters. Established mitogenic signaling causes the removal of Raf-1 and Rb, 
leaving free E2F1 on the proliferative promoters. Finally, all these events promote the cells to 
enter into the S-phase. In another nicotine-induced mitogenic pathway by α7-nAChR, influx 
of Ca
++
 into the cells initiates the ERK and MEKK1 activation. Consequently, MEKK1 leads 
to the activation of NF-kB, which forces cells toward an S-phase entry (Egleton, Brown et al. 
2008). 
 
1.1.5. Effects of nicotine on apoptosis: 
 
Several studies show that nicotine leads to resistance against apoptosis induced by 
extracellular stress stimuli such as opioids, UV radiation, Ca2+ ionophores, neurotoxins, oxi-
dative stress and anticancer drugs; and such resistance might help induce survival in lung 
cancer, oral cancer, and head and neck cancers (Dasgupta, Kinkade et al. 2006; Zeidler, 
Albermann et al. 2007). In addition to cancer cells, nicotine can also protect normal cells 
such as NHBE cells, airway epithelial cells, endothelial cells, human gingival ﬁbroblasts and 
renal epithelial cells against apoptosis induction (Zeidler, Albermann et al. 2007). 
The molecular mechanisms of anti-apoptotic activity of nicotine have been investigated 
by several groups. Figure 1.1.5 shows one of the best models: nicotine exerts its anti-
apoptotic activity via binding to nAChRs or β-adrenergic receptors (Schuller, Tithof et al. 
1999; Trombino, Cesario et al. 2004; Dasgupta, Rastogi et al. 2006). In one route, nicotine 
induces the activity of PKC/MAPK pathway and initiates the phosphorylation of Bcl2 and 
Bad, thereby inhibiting cell death (Mai, May et al. 2003; Xin and Deng 2005; Xin, Gao et al. 
2007). Alternatively, nicotine triggers the activity of PI3K-AKT pathway leading to 
phosphorylation of Bax and Bad and upregulation of XIAP and survivin; so it protects the 
cell against apoptosis (Dasgupta, Kinkade et al. 2006). In addition to these pathways, nicotine 
also stimulates the PKA pathway to protect cells from apoptotic induction (Jin, Gao et al. 
2004). 
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Aside from the anti-apoptotic activity, some studies demonstrate the pro-apoptotic 
activity of nicotine. Berger et al. show the pro-apoptotic effects of nicotine on 
undifferentiated rat hippocampal progenitor cells via induction of p21 and p53 expression 
(Berger, Gage et al. 1998). However, nicotine does not induce apoptosis in cells commenced 
to differentiate. In another study, after treatment of embryonic rat brain with 1, 10 or 100 μM 
nicotine for 48 h, apoptosis takes place (Roy, Andrews et al. 1998). Yamamura et al. find that 
nicotine triggers the influx of Ca
++ 
into cells causing cell death in glioblastoma cell lines 
(Yamamura, Amano et al. 1998). According to these studies, nicotine may induce apoptosis 
in less differentiated embryonic cells especially when cell are treated with higher doses. 
  
14 
 
  
Figure 1.1.5. Model signaling pathways summarizing the anti-apoptotic activity of nicotine 
(Egleton, Brown et al. 2008). 
 
1.1.6. Effects of nicotine on angiogenesis: 
 
Cucina et al., Conklin et al. and Cooke demonstrate that nicotine induces the expression 
of endothelial growth factors like bFGF, PDGF-BB and VEGF, and endothelial nitric oxide 
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synthase (e-NOS) in endothelial cells. These findings encourage researchers to investigate the 
pro-angiogenic activity of nicotine (Cucina, Sapienza et al. 2000; Conklin, Zhao et al. 2002; 
Cooke 2007). Heeschen et al. provide direct evidence for the angiogenic activity of nicotine 
in both the cell culture and animal models. They find that nicotine induces the angiogenic 
tubule formation in collagen gels, upregulates capillary and collateral growth and leads to 
tissue perfusion in ischemic hind-limbs in mouse models. In addition to these, they show that 
nicotine promotes angiogenesis in the Lewis lung carcinoma tumors injected to wild-type 
mice and increase the neovascularization in the sinus of Apo-E-deﬁcient mice (Heeschen, 
Jang et al. 2001; Heeschen, Weis et al. 2002; Heeschen, Weis et al. 2003). 
Recent studies implicate that nicotine promotes angiogenesis and tumor invasion in 
lung and gastric cancers (Shin and Cho 2005; Shin, Wu et al. 2005; Shin, Wu et al. 2007). 
Valenca et al. find that nicotine leads to morphologic alterations in the lungs of Wistar rats 
associated with the increased angiogenesis, inﬁltration of mononuclear cells and irregular 
collapse (Valenca, de Souza da Fonseca et al. 2004). Morimoto et al. use a murine excisional 
wound model and show that nicotine promotes wound healing in addition to its pro-
angiogenic activity (Morimoto, Takemoto et al. 2008). 
Besides the pro-angiogenic activity, several studies suggest that cigarette smoking 
might play key role in metastatic spread of cancer (Murin and Inciardi 2001; Murin, 
Pinkerton et al. 2004). Alteration of cell adhesion to ECM proteins and disruption of cell–cell 
junctions are the important processes of invasion and metastasis. Since the decrease in E-
cadherin and β-catenin with a parallel increase in ﬁbronectin and vimentin is thought to be 
one of the indicators of epithelial to mesenchymal transition, findings of Dasgupta et al. 
reveal that chronic treatment with nicotine leads to the downregulation of ECM proteins, E-
cadherin and β-catenin, and upregulation of ﬁbronectin and vimentin in MCF7 and MDA-
MB-468 breast cancer cells (Dasgupta, Rizwani et al. 2009). In another study, PKC and 
cdc42 have been associated with the nicotine-induced cell migration in MCF7 and MCF10A 
breast cancer cells (Guo, Ibaragi et al. 2008). 
 
1.1.7. The association between smoking and breast cancer: 
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The link between smoking and breast cancer risk is a controversial issue. Most studies 
find that smoking is not associated with an increased risk for breast cancer whereas some 
studies suggest that smoking increases the risk of breast cancer. According to the 2006 US 
Surgeon General’s report, The Health Consequences of Involuntary Exposure To Tobacco 
Smoke, there are some supporting evidence that smoking increases breast cancer risk yet not 
conclusively (ACS 2008). 
However, some of the recent studies have indicated that there is a statistically 
significant association between the breast cancer risk and smoking. For example, relative risk 
(RR) of breast cancer is higher in postmenopausal woman based on a meta-analysis (RR = 
1.21, CI = 1.08-1.36) (Khuder, Mutgi et al. 2001). Furthermore, breast cancer risk increases 
in women who have continued smoking within 5 years of menarche and smoked at least 20 
cigarettes per day (Band, Le et al. 2002). Long-term smoking, estrogen positivity and steroid 
receptor coactivator gene AIB1 genotype also effectively increase breast cancer risk (Colilla, 
Kantoff et al. 2006). For women who continued smoking while having the disease, 
radiotherapy has increased the risk of breast cancer after 10 years (RR = 3.08; 95% CI, 1.61 
to 5.91) (Prochazka, Hall et al. 2005). 
Nicotine, a nicotinic acetylcholine receptor agonist, modulates multiple cellular 
signaling pathways. Although nicotine is the most potent addictive and signal modulatory 
component in cigarette smoke, it has not been studied in detail in the context of breast 
cancers. 
 
1.2. Breast Cancer: 
 
Breast cancer is one of the most common types of cancer, after the lung cancer, and is 
the second leading cause of cancer death among women in the United States. According to 
the American Cancer Society 2009 report, breast cancer is the most frequently diagnosed 
cancer in women except the skin cancer (ACS 2009). Because of hormone dependency in 
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breast cancer, hormonal therapies together with options that include surgery, radio- and 
chemo-therapy have been widely used to treat breast cancer patients (Bai and Gust 2009). 
Again, according to American Cancer Society Report, 192,370 new cases of invasive 
breast cancers are estimated among women and 1,910 new cases are expected in men during 
2009. Incidence of breast cancer has decreased 2.2% per year from 1995 to 2005 (ACS 
2009). This decrease implies the success of improved treatment and earlier diagnosis. To 
date, the 5-year survival of breast cancer patients is 89% while in 1960s it was 63%. The 
survival rate is higher in women diagnosed with localized breast cancer than women 
diagnosed with cancer spreading to the other organs (ACS 2009). 
 
Understanding of histological features and molecular alterations in breast cancer is 
essential to find novel therapeutic approaches with higher success in curing the disease. 
Although breast cancers are extensively heterogeneous, prognostic factors can be classified 
based on three main factors according to Tsuda: (1) the extent of (macro- and 
microscopically visible) tumor spread, (2) biological properties of the cancer cells, and (3) 
host–tumor relationship (Fig. 1.2.1) (Tsuda 2008). 
  
 
Figure 1.2.1. “Prognostic factors of breast cancer. These can be largely categorized into 
factors of: 1 the extent of tumor spread, 2 biological properties if cancer cells, 3 host-tumor 
relationship” (Tsuda 2008). 
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Breast cancer incidence rates are affected by many risk factors. Age, gender, genetics, 
reproductive history, radiation, socio-economic status, place of residence, and ethnicity are 
the best known risk factors in breast cancer (McPherson, Steel et al. 2000; Key, Verkasalo et 
al. 2001; ACS 2008). For example, age of menarche is effective; higher risks of developing 
breast cancer are observed in women having more menstrual cycles due to the higher 
exposure to estrogen and progesterone hormones (McPherson, Steel et al. 2000). Having no 
child or first child at a late age increases the risk of breast cancer (Kvale 1992; Albrektsen, 
Heuch et al. 1995; Lambe, Hsieh et al. 1996). About 5% to 10% of breast cancer is associated 
with the genetic predisposition. The most common inherited mutations in breast cancer 
include BRCA1 and BRCA2 (Easton, Ford et al. 1993; Futreal, Liu et al. 1994; Easton, Ford 
et al. 1995; Gayther, Mangion et al. 1997) while mutations in ATM, CHEK2, p53 and PTEN 
genes also increase the risk for breast cancer development (Starink, van der Veen et al. 1986; 
Swift, Reitnauer et al. 1987; Swift, Morrell et al. 1991). Use of alcohol is associated with 
increased risk of breast cancer, and this risk is correlated with the amount of consumption 
(Key, Verkasalo et al. 2001). 
Breast cancer originates from the epithelial cells of the breast. Mostly, it is seen in 
women, but in rare cases, men can develop breast cancers, as well (Beyrouti, Beyrouti et al. 
2007). Mammary glands are responsible for production of the breast milk; ducts play a role in 
carrying milk from the lobules to the nipple; and the fatty and connective tissue, blood 
vessels, and lymph vessels are the essential parts of the breast (Fig. 1.2.2). In most cases, 
breast cancers start in the ducts (ductal cancer), but sometimes they can be lobular. Several 
types of breast cancer exist but ductal carcinoma in situ (DCIS), lobular carcinoma in situ 
(LCIS), infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC) are the 
most common (Figure 1.2.2). Ductal carcinoma in situ is diagnosed in 25% of the 
mammographic screening programs (Bircan, Kapucuoglu et al. 2006). It is a non-invasive 
type of cancer and women diagnosed with DCIS can be cured (ACS 2008). Similarly, lobular 
carcinoma in situ, also called lobular neoplasia, is classified as a type of non-invasive breast 
cancer; women with LCIS may have increased risk of breast cancer (ACS 2008). Invasive (or 
infiltrating) ductal carcinoma is the most common type of invasive breast cancer and is 
highly heterogeneous.  
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Although factors related the extent of tumor spread and host-tumor relationship are 
important to understand mechanisms underlying breast cancer development and prognosis, in 
this study, we will focus on biological factors used to classify breast cancers and assign 
prognosis, namely, the histological grade and estrogen receptor status. 
 
 
1.2.1. Histological Grade in Breast Cancer: 
 
Histological grade has been considered as a prognostic factor in breast cancer. The 
common histological grading system has been modified from the Bloom and Richardson 
grading system by Elston and Ellis, and now it is known as Nottingham combined 
histological grade (Elston and Ellis 1990). These grading systems are based on three 
morphologic features including percentage of tubule formation, degree of nuclear 
pleomorphism and accurate mitotic count in a defined field area (Ignatiadis and Sotiriou 
2008). Each morphological feature is then scored between 1-3 (Table 1.2.1) and the total 
score determines the grade such that the total scores of 3- 5, 6-7 and 8-9 are considered as 
Grade 1 tumor (well-differentiated), Grade 2 tumor (moderately-differentiated), Grade 3 
tumor (poorly-differentiated), respectively. In terms of grading system, Grade 1 of IDC is 
characterized by lower nuclear grade, and usually hormone receptor–positivity. On the other 
hand, Grade III of IDC shows the higher nuclear grade and hormone receptor negativity and 
genomic instability (Sims, Howell et al. 2007). Similar to IDC, invasive (or infiltrating) 
lobular carcinoma (ILC) can metastasize to other parts of the body (ACS 2008). In addition, 
similar Grading from I to III indicates the degree of nuclear grade and receptor positivity for 
ILC, as well (Sims, Howell et al. 2007). 
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Figure 1.2.2. The anatomy of human breast (ACS 2008).  
 
 Table 1.2.1. Morphological features of breast cancer (imaginis.com) 
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In general, histological grading is a crucial criterion for estimating the risk of 
recurrence of invasive ductal carcinoma and the choice of adjuvant therapies (Goldhirsch, 
Glick et al. 2005; Goldhirsch, Wood et al. 2007). Since higher grade reflects mitotic activity, 
both the histological grade and nuclear grade defined by Tsuda et al. have a common ground 
(Tsuda, Sakamaki et al. 1998). Although independent of tumor size or lymph nodal status, 
histological grade is a prognostic marker that significantly correlates with HER2 
ampliﬁcation, activation of p53, negativity of estrogen and progesterone receptors, and 
accumulation of chromosome alterations (Tsuda 2008). 
 
Gene expression profiling of breast cancer has been extensively studied to identify 
prognostic signatures. However, a common prognostic signature is limited by the number of 
individual studies that significantly support an mRNA or protein marker or a gene expression 
signature, as more recently available through public data resources. In this respect, Sotiriou et 
al. performed a large meta-analysis from the publicly available gene expression and clinical 
data from 2,833 patients and defined co-expression modules for biological processes 
underlying breast cancer development; these processes included proliferation, ER and HER2 
signaling (Sotiriou, Wirapati et al. 2006). Accordingly, it is now possible to classify the 
breast tumors into prognostically significant 3 main groups, namely ER–/HER–, HER2+ and 
ER+/HER2–. In these groupings, proliferation remained the most significant feature of 
histological grading in addition to being a powerful prognostic factor. Indeed, ER- breast 
cancers usually are characterized with high proliferation indices (Ignatiadis and Sotiriou 
2008). Therefore, these findings confirm the correlation of high grade tumor with ER 
negativity (Tsuda 2008). 
 
1.3. Estrogen and Estrogen Receptor in Breast Cancer: 
 
Estrogens, a group of steroid compounds, have important roles during the development 
and maintenance of normal sexual and reproductive system. They also act on cardiovascular, 
musculoskeletal, immune, and central nervous systems in both men and women (Gustafsson 
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2003). 17β-estradiol (E2) is the most potent estrogen produced in the body. Estrogen exerts 
its activity via binding estrogen receptors. Estrogen receptor (ER), a ligand-inducible 
transcription factor, belongs to the nuclear receptor family and has to dimerize for becoming 
active (Heldring, Pike et al. 2007). There are two types of estrogen receptor such as ER-α and 
ER-β although many isoforms of these receptors also are present (Heldring, Pike et al. 2007). 
 
Aside from being important in multiple biological processes, estrogens have a key role 
in the growth and development of breast cancer. In general, estrogen leads to breast cancer 
development via binding to ER-α rather than ER-β (Bai and Gust 2009). Therefore, 
determining the ER status is the most essential factor to identify patients eligible for 
preoperative or postoperative endocrine therapies. Hormone therapy is generally advised to 
treat the ER+/PgR+ patients (Tsuda 2008). Immunohistochemistry (IHC) is mainly used to 
evaluate the presence of ER whereas it is also possible to classify cell lines and/or tumors 
based on profiling of a cluster of genes primarily or secondarily related to estrogen receptor 
mRNA expression (West, Blanchette et al. 2001). 
 
Estrogens and ERs regulate the biological processes in several distinct pathways 
(Fig.1.2.3) (Hall, Couse et al. 2001). There are two possibilities, ER acts upon binding of a 
ligand, or ligand-independently (Heldring, Pike et al. 2007). When the estrogen bound ER 
directly binds to DNA to regulate the gene expression, the mechanism is called classical 
(direct) pathway, which is the most known (Kushner, Agard et al. 2000). Besides the classical 
pathway, the tethered pathway is where the estrogen binds to ER and then interacts with other 
transcription factors; thereby regulation is performed by indirect DNA binding (Saville, 
Wormke et al. 2000). The third pathway known as the nongenomic pathway where estrogen 
activates a membrane associated receptor, either ER located closer to the membrane, or to a 
different receptor, which in turn this binding initiates signaling cascades via second 
messengers such as cAMP. These messengers activate ion channels and produce a rapid 
physiological response without involving gene regulation (Saville, Wormke et al. 2000; 
Simoncini, Mannella et al. 2004; Song, Fan et al. 2006; Song and Santen 2006). On the other 
hand, estrogen receptor also can function in ligand-independent manner (the forth pathway in 
Fig. 1.2.3). In such cases, activated kinases may activate ER through phosphorylation and 
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through growth factor signaling; then activated ERs dimerize, bind DNA and regulate gene 
transcription (Kato, Endoh et al. 1995). This kind of activation of ERs is a novel idea and 
may contribute to hormone-independent growth in some tumors (Coutts and Murphy 1998; 
Heldring, Pike et al. 2007). 
  
Figure 1.2.3. “Model representing the mechanistically distinct molecular pathways used in 
the regulatory actions of ERs” (Heldring, Pike et al. 2007). 
 
Apart from these extensive studies and therapeutic options for the ER-positive breast 
cancer, the mechanisms involved in the biology of ER negative breast cancer are unclear. The 
common knowledge is that ER negative breast cancer is more aggressive than ER positive 
breast cancer; in ER- cancers, growth is independent of estrogen thus the cancer cell is 
resistant to hormone therapy (Sheikh, Garcia et al. 1994; Massarweh and Schiff 2006). There 
are multiple mechanisms defined for the down-regulation or the loss of ER expression and 
ER negative breast cancer development. One of the suggestions is the loss of heterozygosity 
or accumulation of mutations in the ER gene locus but LOH or mutations might not always 
lead to ER expression loss (Iwase, Greenman et al. 1995; Herynk and Fuqua 2004; Holst, 
Stahl et al. 2007). On the other hand, a well-documented possibility is the hypermethylation 
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of CpG islands within the ER promoter. Epigenetic silencing has been found in 25% of ER-
negative breast cancers (Yang, Phillips et al. 2001; Giacinti, Claudio et al. 2006).Other 
possibilities include the altered activity of transcription factors acting on the ER promoter 
(Castles, Oesterreich et al. 1997; Reid, Denger et al. 2002), mRNA degradation via miRNAs 
(Reid, Denger et al. 2002; Adams, Furneaux et al. 2007), postranscritional modification 
leading to degradation (Stoner, Saville et al. 2002), and finally silencing at the mRNA and 
protein levels via hyperactivity of growth factor receptor (GFR) signaling (Holloway, Murthy 
et al. 2004; Creighton, Hilger et al. 2006; Bayliss, Hilger et al. 2007). In addition, 
hyperactivity of GFR signaling and its intermediates can lead to resistance to endocrine 
therapy (Lopez-Tarruella and Schiff 2007). 
 
Restoring the ER function is one of the most powerful therapeutic approaches to cure 
the ER-negative breast cancer patients. One of them is the treatment of ER-negative breast 
cancer with histone deacetylase inhibitors or agents inducing DNA demethylation to restore 
ER-positivity (Yang, Phillips et al. 2001; Sharma, Smith et al. 2006). Another approach is 
using a MAPK blockade to decrease the GFR/MAPK signaling activity (Bayliss, Hilger et al. 
2007). After restored ER functions, hormonal therapy might be used to treat the patients.  
 
1.3.1. Hormone Therapy in Breast Cancer: 
 
Anti-estrogens are used to inhibit the physiological activities of E2 to prevent the 
development of cancer in hormone therapy. Tamoxifen is the most common anti-estrogen 
used in hormone therapy (Clarke, Liu et al. 2003). Although it functions as anti-estrogen in 
breast cancer, it might act also as an estrogen agonist in some other tissues including the 
bone, uterus, liver, and the cardiovascular system (McDonald and Stewart 1991; Rutqvist and 
Mattsson 1993; Nuttall, Stroup et al. 2000; Chlebowski 2005). These agonistic activities 
present advantages for the woman taking tamoxifen to enhance the bone maintenance while 
protecting the blood-lipid profile and decreasing the coronary risk (McDonald and Stewart 
1991; Dewar, Horobin et al. 1992). On the other hand, its agonistic activity stimulates the 
endometrial hyperplesia in uterus and may function as a carcinogen in liver (Gal, Kopel et al. 
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1991; Ahotupa, Hirsimaki et al. 1994; Barakat 1996). The mechanism by which Tamoxifen 
works is through competition with estrogen to bind the ER. Upon binding, it alters the 
conformation of ER and thereby, blocks the ER dimerization and binding to DNA or to co-
activators, or makes the ER favorable to bind co-repressors (Huang, Norris et al. 2002; Shang 
and Brown 2002). Therefore, Tamoxifen inhibits the estrogen-induced growth of breast 
cancer. Another anti-estrogen used in breast cancer is RAL. Its activity is very similar to 
tamoxifen but it blocks the endometrial cancer growth (Swaby, Sharma et al. 2007). Recent 
studies indicate that aromatase inhibitors produce better results than tamoxifen treatment (Bai 
and Gust 2009). 
 
Despite estrogen-like activity of tamoxifen, pure anti-estrogens, such as fulvestrants, do 
not have any agonistic effects. Fulvestrants interact with newly synthesized ER in the 
cytoplasm and inhibit their nuclear transportation; the inhibited receptor is then degraded 
(Dauvois, Danielian et al. 1992). Despite the initial response to hormone therapy, the tumor 
may exhibit recurrence upon long-term therapy where patients become resistant to multiple 
therapies. There are two main pathways leading to resistance to therapy: intrinsic (de novo) 
and acquired (Hurvitz and Pietras 2008). Genetic polymorphism is one of the reasons for the 
intrinsic resistance to tamoxifen however the intrinsic resistance mechanisms need further 
study (Beverage, Sissung et al. 2007; Schroth, Antoniadou et al. 2007). On the other hand, 
many studies focus on the acquired resistance. Activation of ER-regulated growth factor 
pathways independent of steroid control, hyperactivity of GFR signaling and its components, 
constitutively active ER mutants or variants are some of the mechanisms to elucidate the 
acquired resistance (Fuqua, Wiltschke et al. 2000; Schiff, Massarweh et al. 2003; Schiff, 
Massarweh et al. 2004; Normanno, Di Maio et al. 2005). Recent studies focus on the 
understanding of the resistance mechanisms and improvement of the endocrine therapy 
which is still one of the best therapies for the breast cancer patients (Hurvitz and Pietras 
2008). 
 
 
1.3.2. Cell Culture Cancer Models 
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1.3.2.1. MCF7 Cells as a Model For The Estrogen Studies: 
 
MCF7 is an ER-α positive breast cancer cell line and its growth depends on the 
presence of estrogen. In addition, distinct types of clones can be obtained under certain 
conditions that alter the estrogen-sensitivity. Highly-sensitive MCF7/ BUS cells, estrogen-
independent MCF7:2A and MCF7:5C cells, and drug resistant MCF7 cells are some of the 
examples (Pink, Jiang et al. 1995; Villalobos, Olea et al. 1995; Coser, Chesnes et al. 2003; 
Fan, Yan et al. 2006). These modified types of clones help researchers understand the 
estrogen signaling and hormone resistance mechanisms. 
 
1.3.2.2. Effects of serum starvation on cells: 
 
Serum starvation is widely used to obtain synchronized cells. Since serum starvation 
prevents TOR protein activity and decreases the levels of cyclin D1, it leads to cell cycle 
arrest in the G0/G1 phase (Kues, Anger et al. 2000; Cooper 2003; Demidenko and 
Blagosklonny 2008). Under serum starved conditions, the entry into S phase does not occur. 
If the cell cycle arrest is induced by serum starvation, the DNA synthesis stops (Cooper 
2003). Kim et al. suggest that under serum withdrawal, MRPL41, mitochondrial ribosomal 
protein L41, leads to cell cycle arrest via increasing the p21 (WAF1/CIP1) and p27 (Kip1) 
levels (Kim, Yoo et al. 2005). Shin et al. use SK-OV-3 ovarian cancer cells. They show that 
serum starvation induces the G1 cell cycle arrest without causing cell death and decreases 
Skp2, CDK2 and CDK4 in protein level. Since Skp2 suppresses the p27 activity, Skp2 
indirectly enhances the CDK2 activity (Shin, Hong et al. 2008). Therefore, they suggest that 
serum starvation leads to cell cycle arrest via decreasing Skp2, CDK2 and CDK4 proteins 
(Shin, Hong et al. 2008). In another study, serum starvation suppresses Cdc6 at both the 
mRNA and protein levels in human diploid fibroblasts, and the addition of serum re-
establishes the expression (Williams, Shohet et al. 1997). Since PKCη interacts with cyclin E 
in the absence of serum, serum starvation may inhibit the kinase activity of cyclin E/Cdk2 
complex via PKCη (Shtutman, Hershko et al. 2003). 
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Besides the cell cycle arrest, serum starvation can trigger apoptosis. Hasan et al indicate 
that serum starvation of V79 cells activates the p53, whose activity depends on PKC-α 
(Hasan, Adams et al. 1999). On the other hand, Ming et al. use the p53 mutant cell lines to 
examine apoptotic effect of serum starvation (Ming, Sakaida et al. 2008). They find that 
serum starvation causes the transcription factors SP1 and p73 to bind the promoter of PUMA 
and induce the expression through a p53-independent mechanism. In another study, Raf-1 has 
a protective role in response to serum starvation in fibroblasts (Mikula, Schreiber et al. 2001). 
Thiel et al. suggest that the signaling cascade BDNF → TrkB stimulation → PI3 kinase 
activation → activation of AKT is essential to rescue the cell from serum withdrawal induced 
apoptosis (Thiel, Ekici et al. 2009). eIF4E, eukaryotic initiation factor 4E, mediates the gene 
expression to activate AKT; and AKT activation protects cells from apoptosis while eIF4E 
prevents apoptosis induced by serum starvation (Culjkovic, Tan et al. 2008). Lu et al. use 
HaCat cells and MEF cells in their studies showing that serum starvation leads to 
phosphorylation of H2AX, a variant of the histone H2A family, and p38 (Lu, Shi et al. 2008). 
Since blocking p38 abrogates the H2AX phosphorylation and apoptosis, they conclude that 
serum starvation induces apoptosis via signaling pathway, p38/H2AX. The role of caspases is 
unclear in serum starvation induced apoptosis; and the outcome depends on the cell culture 
model system. Haviv et al. identifies caspase-2 as the main activator in PC-12 cells whereas 
caspase-12 has an essential role in mouse AKR2-B fibroblasts (Zhu, Cowie et al. 1996; 
Haviv, Lindenboim et al. 1998). On the other hand, Schamberger et al. find that caspase-8 
and caspase-3 initiate apoptosis in rat 423 cells (Schamberger, Gerner et al. 2004). Taken 
together, the role of caspases in apoptosis in response to serum starvation depends on the cell 
culture model. 
 
1.4. Microarray Technology: 
 
The discovery of microarray technology is one of the biggest developments in biology 
(Pease, Solas et al. 1994; Schena, Shalon et al. 1995). DNA microarrays provide an 
opportunity for researchers to carry out large-scale quantitative experiments simultaneously. 
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Alterations in the expression rate of nearly all the genes in a genome, occuring in a particular 
tissue or cell type, can be measured in disease states, during development, and in response to 
gene disruptions or drug treatments. Profiling of gene expression patterns allow discovering 
the mechanisms of disease and identifying disease subphenotypes, predicting disease 
progression, providing functional information for the unannotated genes, grouping genes into 
functional pathways, and estimating the activities of new compounds (Hughes, Roberts et al. 
2000; Waring, Ciurlionis et al. 2001; Chuaqui, Bonner et al. 2002; Lock, Hermans et al. 
2002; Ntzani and Ioannidis 2003; McMillian, Nie et al. 2004; Miklos and Maleszka 2004). In 
addition to expression profiling, microarrays are designed from genome sequence itself to 
discover novel genes, and binding sites of transcription factors, identify the alterations in 
DNA copy number, and variations from a baseline sequence, such as in emerging strains of 
pathogens or complex mutations in disease-causing human genes (Stoughton 2005). Multiple 
microarray studies can also be compared using a relatively relaxed p value and higher fold 
changes (Fan, Shi et al. 2009). 
Besides the increased use of gene expression profiling, the analysis of such data has 
serious problems (Michiels, Koscielny et al. 2005). Statistical knowledge is essential to 
perform a valid analysis of microarray data, whereas there are a few statisticians familiar 
with the microarray data despite the use of microarrays in many laboratories. Therefore, 
biostatisticians of the Biometric Research Branch of the National Cancer Institute develop the 
BRB-ArrayTools, which is non-commercial and user-friendly microarray analysis tool. In 
addition to normalization of the microarray data, it has many objectives to perform further 
analysis. Class comparison is one such methodology and provides the users with ability to 
identify the differentially expressed genes among groups of specimens collected from 
different types of tissues or under different experimental conditions. Another important 
method is the class prediction. It is used to predict the class of a sample based on its 
expression profile. Survival risk group prediction is the other important objectives for 
standard clinical and pathological prognostic factors. In addition to these objectives, it has 
many statistical tools such as cluster analysis, ANOVA, time-series analysis (Simon, Lam et 
al. 2007). 
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The development of high-throughput technologies, especially microarray technologies, 
provides the researchers to produce the large-scale expression datasets. This development 
requires the development of bioinformatics tool to technologies to analyze tens of thousands 
of genes simultaneously. WebGestalt, web-based integrated datamining system, developed by 
Zhang groups is one of the essential tools to explore large gene sets. It is a user-friendly 
bioinformatics tools to help the users for the management, information retrieval, 
organization, visualization and statistical analysis of gene sets. It has different types of 
methods such as Gene Ontology analysis, pathway analysis, and protein domain analysis 
(Zhang, Kirov et al. 2005). 
 
1.4.1. Microarray studies on nicotine-mediated signaling: 
 
There exist a number of microarray studies focusing on different aspects of nicotine 
mediated signaling both in a neuronal and non-neuronal context. For example, human 
bronchial epithelial cells go through a large-scale change in their transcriptional profiles upon 
exposure to 5 μM nicotine (4-10 hours) (Tsai, Chong et al. 2006). Cellular signaling 
pathways responsive to nicotine include ERK and interleukin-8 signaling (Tsai, Chong et al. 
2006). Saito et al. based on their study of nicotine-induced changes in brain revealed that 
multiple MAPK signaling components, GABA receptors and protein phosphatases were 
involved. Nicotine also acts differentially on rat brain tissues; genes affected by nicotine play 
important roles in PKC, MAPK, NF-kappaB, and ubiquitin/proteosome signaling pathways 
(Konu, Kane et al. 2001; Li, Konu et al. 2002; Kane, Konu et al. 2004; Saito, O'Brien et al. 
2005). On the other hand, microarray studies performed using PC12 indicate that nicotine 
might lead to modulation of several growth factors, heat-shock proteins, ribosomal and 
proteosomal subunit expression together with mRNAs involved in mTOR signaling (Konu, 
Xu et al. 2004). These studies are supportive of the findings that nicotine modulates 
PI3K/AKT/PTEN/TOR signaling pathway elements. Although nicotine’s cellular effects 
were studied in neuronal cell lines and tissues, no such study exists for breast cancers. 
Considering that nicotine’s effects might be dependent on the state of the cells, i.e., actively 
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proliferating or growth-arrested may provide important insight into the regulation of cell 
proliferation/growth related signaling pathways. 
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CHAPTER 2: MATERIALS AND METHODS 
2. Materials and Methods 
2.1. Materials: 
 
General Reagents: The general laboratory chemicals were supplied from Sigma 
Chemical Co. (St. Louis, USA), Merck (Darmstadt, Germany), Stratagene (Heidelberg, 
Germany) and AppliChem (Darmstadt, Germany). 
Proteins: Protein size marker was from MBI Fermantas (PageRuler Prestained, 
SM0671). 
Protein transfer materials: Immobilen P transfer (PVDF) membrane was from Roche 
(Germany), and 3MM filter paper was from Whatman International Ltd. (Madison, USA). 
Photography and autoradiography: The films used for autoradiography were from 
KODAK (Rochester, USA) and the development of the films was performed with 
Hyperprocessor (Amsderdam, UK). 
Tissue reagents and cell lines: Dulbecco’s Modified Eagle’s Medium (DMEM), and 
trypsin were obtained from Biochrom (UK); fetal bovine serum, penicillin/streptomycin, and 
non-essential amino acid were supplied from Hyclone (Logan, USA). MCF7 is a human 
breast carcinoma cell line was obtained from ATCC (HTB-22) and kindly provided by I. 
Yulug, at Bilkent University, Dept. Molecular Biology and Genetics.  
Kits: The RNA isolation kit was from Promega (Madison, USA; Z3100). ECL plus 
western blotting reagent was from Amersham (UK; RPN2132) and SuperSignal West Femto 
reagents were obtained from Perbio (UK; 34095). Vybrant MTT cell proliferation kit was 
obtained from Invitrogen (USA; V13154). 
Microarrays: HG-U133 plus 2 microarrays and reagents were supplied from Affymetrix 
(USA). 
Treatment reagents: Nicotine was supplied from Sigma (USA; 54-11-5). 
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Antibodies: p53 (BD Pharmingen, USA; 554290), calnexin (Sigma, USA; C4731) 
antibodies, and anti-mouse HRP conjugated secondary antibody (Sigma, USA; A0168) were 
kindly provided by M. Ozturk at Bilkent University, Dept. Molecular Biology and Genetics. 
Bcl-xl (Santa Cruz, USA; sc-8396) and cyclinE (Santa Cruz, USA; sc-481) antibodies were 
kindly provided by K. Can Akcali, at Bilkent University, Department of Molecular Biology 
and Genetics. Anti-rabbit HRP conjugated secondary antibodies was obtained from Santa 
Cruz (USA; sc-2004). 
 
2.2. Solutions and media 
 
2.2.1. General solutions:  
 
10X PBS: 40 gr NaCl, 1 gr KCl, 7.2 gr Na2HPO4 and 1.2 gr KH2PO4 were dissolved in 
400 ml dH2O and pH was adjusted to 7.4 with HCl. ddH2O was added to complete the final 
volume 500 ml. 
2 M NaCl: 58.44 gr NaCl in 500 ml dd . ddH2O. 
10% SDS: 100gr SDS was dissolved n 900 ml ddH2O and heated to 68 
0 
C to assist 
dissolution. Then, pH was adjusted to 7.2 and the final volume was completed to 1lt by 
adding ddH2O. 
 
2.2.2. Tissue culture solutions: 
 
Growth medium: DMEM was supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin and 1% non-essential amino acids. 
Starvation medium: DMEM was supplemented with 0.1% fetal bovine serum, 1% 
penicillin/streptomycin and 1% non-essential amino acids. 
Freezing solution: 5% DMSO and 95% growth media were mixed. 
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1XPBS: 1X PBS was prepared from 10X PBS stock solutions and pH was adjusted pH 
at 7.4 followed by autoclaving and filtering before use. 
Nicotine treatment solutions: 2 μl of nicotine was dissolved in 1248 μl of starvation 
medium to make a 10 mM nicotine stock solution. For dilutions, a 10 μM nicotine solution 
was prepared from the 10 mM Nicotine stock solution. All studies were performed in the 
dark. For each experiment, 10 mM Nicotine stock solution was prepared fresh. 
 
2.2.3. Protein Extraction and Western blotting solutions: 
 
NP40 lysis buffer: 150 mM NaCl, 50 mM Tris.Cl at pH 8.0, 1% NP40 and 1X protease 
inhibitor mix were mixed in dd H2O. 
Bradford working solution: 10 mg Coomassie brilliant blue was dissolved in 5 ml 
95% ethanol and 10 ml 85% phosphoric acid. ddH2O was added to complete the final volume 
at 1 lt. Then, the solutions were filtered by using Whatman paper and stored at 4+ 
0
C in dark. 
30% Acrylamide-bisacrylamide solutions: 29 gr acrylamide and 1 gr biacrylamide 
were dissolved in 100 ml ddH2O and stored at 4+ 
0
C in the dark. 
10% APS: 0.15 gr ammonium per sulfate was dissolved in 1 ml ddH2O. 
1.5 Tris, pH 8.8: 54.45 gr Tris-base was dissolved in 150 ml dH2O and pH was 
adjusted with 1 N HCl to 300 dH2O. It was stored at 4+ 
0
C. 
1M Tris, pH 6.8: 12 gr Tris-base was dissolved in 60 ml dH2O and pH was adjusted 
with 1 N HCl to 100 dH2O. It was stored in at 4+ 
0
C. 
2X protein loading buffer: 50 mM Tris. HCl at pH 6.8, 2 mM EDTA at pH 6.8, 1% 
SDS, 10% glycerol and 0.02% Bromophenol blue solutions. 
5X Running Buffer: 15 gr Tris.base, 72 gr Glycine and 5 gr SDS were dissolved in 
ddH2O and completed the final volume to 1 lt. 
Semi-dry transfer buffer: 2.5 gr Glycine, 5.8 gr Tris base, 3.7 ml 10% SDS, 200 ml 
MeOH were dissolved in ddH2O and completed the final volume to 1 lt. 
10X TBS: 12.19 gr Tris-base and 87.76 gr NaCl were dissolved in 1 lt of ddH2O. 
TBS-T: 0.1% Tween 20 was added into a 1XTBS solution and the pH was adjusted to 
7.4. 
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Blocking Solution: 2.5 gr milk powder was dissolved in 50 ml 1X TBS-T (0.1%). 
 
2.3. Laboratory Methods: 
 
2.3.1. Tissue Culture techniques: 
 
Growth conditions of MCF7 cell line: MCF7 breast carcinoma cell line was used as 
the cell line model system. MCF7 cell line was derived from 69 year-old Caucasion female 
and is a p53 positive and ER+ cell line. MCF7 cell line was maintained in Dubecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% 
non-essential amino acids and 1% penicillin/streptomycin. The cells were incubated at a 37
0
C 
incubator with an atmosphere of 5% CO2 in air. The cells were passaged every 3-4 days 
before reaching confluence. The growth medium was aspirated and cells were washed with 
1X PBS twice; trypsinized; and were dispersed by pipetting with fresh medium before cells 
were transferred to a new flask using a given set of dilutions depending on requirements. 
DMEM and PBS were kept at 4 + 
0
C, trypsin was kept at - 20
0
C. All solutions were warmed 
to 37
0
C before use. 
Cryopreservation of cell lines: Exponentially growing cells were harvested by using 
trypsin and neutralized by adding fresh growth medium. The cells were precipitated at 1200 
rpm for 3 minutes. The cells were then re-suspended with freezing media, i.e., 5% DMSO in 
growth medium. Then, cells in the freezing media were transferred into two cyrotubes and 
stored at -80
0
C overnight and then transferred to the liquid nitrogen tank for long-term 
storage. To re-culture the frozen cells, they were thawed rapidly at 37
0
C and mixed with 3 ml 
growth medium; and centrifuged at 1200 rpm for 3 minutes. After removal of the 
supernatant, the cells were re-suspended with fresh growth medium. Cells were grown in 75 
cm
2
 flask in the incubator. 
 
2.3.2. Nicotine treatment protocol: 
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Time- and dose-dependent nicotine treatment experiments: Cells were harvested by 
trypsinization; neutralized by adding fresh media; and were counted. For 2 days treatment, 
5000 cells/ well; for 3 days, 3000 cells/well; for 5 and 7 days, 1000 cells/well were seeded to 
the 96 well-plates. There were four conditions: control (no treatment), 0.1, 1 and 10 μM 
nicotine treatment and each condition consisted of 4 replicates. The cells were incubated for 
24 h to attach the surface of the plate. After 24 h, the cell media were removed and cells were 
incubated in the starvation media for 24 h to obtain quiescent cells. For the 10% serum 
treatment, the treatment media (0.1, 1 and 10 μM nicotine in media) were prepared with 
growth media and for the 0.1% serum treatment, media with 0.1% FBS were used for all 
experimental groups (0.1, 1 and 10 μM nicotine in media). After obtaining quiescent cells, all 
media were removed and replaced with freshly prepared treatment media for the 2 days and 3 
days experiments. For 5 days and 7 days experiment, first, cells were incubated with the 
treatment media for 3 days and then the media were replaced with freshly prepared treatment 
media. The cells were then incubated in fresh media for 2 days (5 days experiment), or 4 days 
(7 days experiment).  
 
MTT proliferation assay: To measure the cell proliferation, Vybrant MTT cell 
proliferation kit were used. 1 ml of 1X PBS was added to the each tube and mixed well. The 
treatment media was removed; 100 μl of starvation medium was added to cells in each well 
followed by addition of 10 μl of MTT solution. The cells were incubated for 4 h; the media 
with MTT solution was removed and 100 μl DMSO was added. After 10 min of incubation, 
the plates were read in Elisa-reader (Company, City) at 540 nm wavelengths. During 
analysis, blank wells were used as background and an averaged blank reading value was 
subtracted from the values obtained from treatment wells. 
 
Nicotine treatment for RNA and protein experiments: Cells were harvested upon 
trypsin treatment and neutralized by adding fresh media; and then counted. For the 10 % 
serum conditions, 1.2 X10^6 cells were seeded to the 75 cm
2
 flask in growth media and were 
incubated for 24 h for attachment. Then, the cells were incubated in the starvation medium 
(0.1% FBS) for another 24 h. After synchronization, the treatment media were added (growth 
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media + 10% FBS for control cells or growth media + 10% FBS + 1μM nicotine) and cells 
were incubated in the treatment medium for another 48 h. On the other hand, for the 0.1% 
serum treatment, 2X10^6 cell were seeded to the 75 cm
2
 flasks and incubated in the growth 
media for 24 h for attachment followed by 24 h serum starvation for obtaining quiescent 
cells. The 48 h treatment medium contained growth media supplemented with 0.1% FBS, and 
0 or 1 μM nicotine. Upon completion of the experiments, cells were scraped in ice-cold 1X 
PBS; precipitated at 1200 rpm for 3 min; and the cell pellets were stored at -80
0
C for further 
experiments. Each experiment included 3 biological replicates for the RNA and protein 
extractions. 
 
2.3.3. RNA experiments: 
 
Total RNA isolation: Total RNA isolation was performed using Promega SV Total 
RNA isolation kit according to the manufacturer’s instructions. The RNA was eluted in a 
total volume of 50 μl. The concentration of the isolated RNA and the ratio of absorbance at 
260 nm to 280 nm were measured with the Nanodrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Montchanin, USA). If the concentration of RNA was found less 
than 625 ng/μl the samples were vacuum dried to concentrate the RNA since 5 μg RNA in 8 
μl was needed for the microarray experiments. The integrity of isolated RNA samples was 
measured with the Agilent 2100 Bioanalyzer (Agilent Technologies, USA). Isolated RNA 
samples were stored at -80
0
C. 
 
2.3.4. Protein experiments: 
 
Protein extraction: The cell pellets were lysed in the NP40 lysis buffers by vortexing 
every 5 min for half an hour on ice. Then, they were centrifuged at 13000 rpm for 30 min at 
4+ 
0
C; the supernatant was collected and stored at -80 
0
C for Western blotting experiments. 
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Quantification of protein concentrations: The concentration of a cell lysate was 
measured by Bradford assay. 2 μl of each sample or lysis buffer (for the blank) was mixed 
with 98 μl of ddH2O and then 900 μl of Bradford working solution was added to the sample 
and mixed well. After 5 min of incubation, the protein concentrations were measured at 
OD595 nm versus the blank reagent. For the standard curve, 1 mg of BSA was measured and 
dissolved in 1 ml of ddH2O. Then, 0, 1, 2, 4, 8, 16, and 32 μl of BSA solution was mixed 
with 100, 99, 98, 96, 92, 84 and 68 μl of ddH2O, respectively and 900 μl of Bradford working 
solution was added to the sample and mixed well. After 5 min of incubation, the OD595 nm 
values were measured; and the standard curve was plotted with these values. The unknown 
concentrations of the samples were calculated from the standard curve. 
 
Western blotting: 
SDS polyacrylamide gel electrophoresis: Resolving gel (12% polyacrylamide gel; 15 
ml) was prepared as below: 
dH2O   4.9 ml 
30% Acrylamide mix 6.0 ml 
1.5 M Tris, pH=8.8 3.8 ml 
10% SDS   15O μl 
10% APS   150 μl 
TEMED   6 μl 
Stacking gel (5% polyacrylamide gel; 8 ml) was prepared as below: 
dH2O   5.5 ml 
30% Acrylamide mix 1.3 ml 
1.0 M Tris, pH=6.8 1 ml 
10% SDS   80 μl 
10% APS   80 μl 
TEMED   8 μl 
Equal amount of proteins were mixed with the 2X loading buffer containing 1% β-
mercaptoethanol and boiled for 5 min to denature the proteins. Then, the samples and the 
Fermentas PageRuler Protein size marker were loaded on gel. Gels were run at 80 V for the 
stacking gel and 120 V for the resolving gel in running buffer.  
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Protein transfer to solid support: Since all proteins were smaller than 120 kda, semi-
dry transfer was performed. Whatman paper and the PVDF membrane were cut at suitable 
sizes. The membranes were incubated in 100% methanol for 30 seconds and then, incubated 
with ddH2O for 2 min. After that, Whatman papers and membrane were incubated in the 
semi-dry buffer for 5 min. Then the following arrangement shown in Figure 2.3.1 was 
applied to transfer proteins. 
 
 
Figure 2.3.1. The schematic representation of semi-dry transfer (Fermentas). 
Immunological detection of immobilized proteins: After transfer, the membrane was 
immersed in the 5% blocking solution for an hour on a slowly rotating platform to inhibit 
non-specific binding. Upon blocking, the membrane was washed with TBS-T (0.1%) three 
times, each for 10 min. Each antibody was diluted in the blocking solution at different 
concentrations: calnexin: 1/500, Bcl-xl: 1/500, cyclin-E: 1/200 and p53: 1/1000. The 
membrane was incubated with the primary antibody solutions for overnight at 4+ 
0
C on a 
slowly rotating platform. The membrane was washed with TBS-T (0.1%) three times, each 
for 10 min. The appropriate HRP-conjugated secondary antibody was diluted in blocking 
solution (1:5000, as recommended by supplier). The membrane was incubated with the 
secondary antibody solutions for an hour at room temperature again on a slowly rotating 
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platform; washed with TBS-T (0.1%) three times, each wash for 10 min. The membrane was 
treated with ECL plus reagent (or Femto reagents depending on the protein signal) according 
to the manufacturer’s instructions and then wrapped with stretch film. The autoradiography 
was performed for various exposure times. 
 
 
2.3.5. Microarray analysis:  
Data normalization: All microarray experiments were carried out on Affymetrix U133 
plus 2 GeneChips. 5 μg RNA in 8 μl was used for each sample. Amplification, labeling and 
hybridizations were done under the supervision of Asssociate Prof. Işık Yuluğ by the 
Genomics Core Facility assistant according to the manufacturer’s protocols. Affymetrix 
analysis software (GCOS) was used to perform the preliminary probe-level quantification of 
the microarray data for initial analysis including quality control. These data were further 
normalized with the RMA normalization method using the BRB-Array tools, 3.7 Version. 
The default option of RMA (with background correction, quantile normalization, and log 
transformation) was used to generate the normalized intensity for each probeset. Quality 
control of the arrays were performed using an option in BRB-Array tools, which provide 
measurements on the RNA degradation parameters, and factors such as scaling factor and 
background. 
Selection of differentially expressed genes: Differentially expressed genes were 
identiﬁed at each time point separately using the untreated 0.1% serum or 10% serum 
controls against 0.1% serum 1 μM nicotine-treated samples or 10% serum 1 μM nicotine-
treated samples, respectively. To find the differentially expressed genes, BRB-Array Tools 
were used for all analysis. A 1.2 fold change was used as the cut-off for 10% serum 
experiment analysis. Unpaired-class comparison analysis with/without blocking batch effect 
(i.e., different days of hybridization) were performed at the p<0.05. After that, the common 
probe ID’s to both paired and unpaired class comparisons were used for further analysis.  
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Due to presence of a single replica of each condition in the 0.1% serum treatment 
experiment, a 1.5 fold change value was used as the cut-off to determine a potential list of 
differentially expressed genes. On the other hand, when comparing the gene expression of 
10% serum control samples to the 0.1% serum control or to the 1 μM nicotine-treated 
samples, this probeset list from the 0.1% serum analysis was used as a focused gene-set. 
Focused gene sets have been frequently used in microarray meta-analysis to test the change 
of expression for a given set of genes, which may be unique to a biological process or altered 
under a particular treatment. Then, these probesets were separated into two groups: 1) probes 
whose expression in response to 0.1% serum 1 μM nicotine-treatment with similarities to 
those from 10% serum control samples rather to the 0.1% serum control samples; and 2) 
probes whose expression in response to 0.1% serum 1 μM nicotin-treatment behaved unlike 
of the 10% serum control samples.  
 Gene Ontology (GO) Analysis: After determining the differentially expressed 
probesets, the GO analysis was performed to find the biological processes that were altered 
via nicotine treatment and to assign potential function to the probesets differentially 
expressed. To perform the GO analysis, Webgstalt (WEB-based GEne SeT AnaLysis 
Toolkit; http://bioinfo.vanderbilt.edu/webgestalt) was used. When performing the GO 
analysis, hyper-geometric tests were used at p<0.05 and presence of two genes in each 
category was selected as a minimum requirement. GO levels 4, 5 or 6 were chosen for the 
biological level and molecular functions graphics. If the groups were significant according to 
selected criteria, the significant categories were shown in red color. In addition to GO 
analysis, Biocarta and KEGG pathway analyses were performed using similar protocols. 
Cluster analysis: Cluster analysis is commonly used to identify the degree of 
association between objects. If the degree of association is high between the objects, they are 
put into the same group, and if the degree of association is low between the objects, they are 
categorized separately. During the cluster analysis, median gene centering was used before 
hierarchical clustering: Genes and arrays were clustered; un-centered correlation coefficient 
was calculated to find the similarity matrix; and finally, average linkage method was chosen 
for the analysis. Cluster analysis was performed using the Cluster 3.0 software program and 
the image analysis was done by using Java TreeView software (Saldanha 2004). 
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2.4. Microarray Meta-analysis 
2.4.1. Preparation of expression data: 
Publicly available datasets were collected from Gene Expression Omnibus (GEO) 
(Tables 2.4.1 and 2.4.2). To eliminate the heterogeneity of different microarray platforms, we 
used only Affymetrix HG-U133A and HG-U133 plus 2 platforms because they both have a 
single probeset for CHRNA5, 206533_at. 
Table 2.4.1. Publicly available gene expression data from estrogen studies on cell lines 
. 
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Table 2.4.2. Publicly available gene expression data from primary breast cancer studies. 
 
 
2.4.2. Features of the breast cancer microarray experiments: 
 Clinical information of breast cancer data sets used in our analysis was presented in 
Table 2.4.3. 
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Table 2.4.3. The distribution of data according to ER, grade and treatment status. 
 
Some datasets from GEO or arrays from the datasets were not analyzed herein for the 
following reasons indicated below: 
GSE1456 performed by Pawitan et al. was eliminated because it did not have 
information about the samples either from untreated or treated patients (Pawitan, Bjohle et al. 
2004). 
 GSE6532  Loi et al. had 741 arrays in three different platforms: HG-U133A, B and 
plus 2. Due to the absence of probeset for CHRNA5, data performed in HG-U133B was not 
analyzed. Dataset performed in HG-U133 plus2 was from ER+ Tamoxifen treated patients. 
Data was analyzed but the average absolute expression value of CHRNA5 was lower than 16, 
which is not detectable by PCR, so it was not included in our analysis (Loi, Haibe-Kains et 
al. 2007; Loi, Haibe-Kains et al. 2008).  
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GSE4922 Ivshina et al. had 578 arrays performed in two different platforms: HG-
U133A and HG-U133B. Similar to GSE6532, the dataset in HG-U133B was not analyzed. 
On the other hand, NUH-sample series were eliminated due to the absence of information 
about ER status and treatment (Ivshina, George et al. 2006). 
GSE5460 Darkee et al. had 129 arrays but 35 arrays could not read from BRB- 
ArrayTool. Therefore, the analysis was performed with only 94 arrays (Dairkee, Seok et al. 
2008). 
 
2.4.3. Experimental features of the in vitro public microarray experiments: 
GSE3529: Three different ER-α positive estrogen dependent MCF7, T47D and BT-474 
breast cancer cell lines were used. Before the estrogen treatment, cells were washed and 
grown in steroid depleted phenol red-free IMEM media supplemented with 10% charcoal 
stripped FBS for three days. After that, cells were treated with E2 for 24 hours (Rae, Johnson 
et al. 2005). 
GSE11791: MCF7 cells were grown in media supplemented with 10 nM ICI 182780 
for 48 hours before the treatment. Then, cells were treated for 6h with either 100 nM E2 or 
ethanol vehicle. As in the GSE11467, this data set contains different treatments in addition to 
E2, which were eliminated from further analysis in the present study (Musgrove, Sergio et al. 
2008). 
GSE4668: MCF7/BUS cells were maintained in DMEM supplemented with 5%FBS. 
Before the treatment, cells were washed three times with phenol red-free DMEM 
supplemented with 5% charcoal-dextran stripped FBS and then grown in the presence of 
varying concentrations of E2 (0 pM, 10 pM, 30 pM, 60 pM, and 100 pM) for 48 hours. In 
another experiment, MCF7/BUS cells were subjected to hormone starvation for 0, 1 or 2 days 
(Coser, Chesnes et al. 2003). 
GSE11324: MCF7 cells were grown in a hormone-deprived media for 24 hours before 
the treatment. Then, cells were stimulated with 100 nM estrogen for 0, 3, 6 or 12 hours 
(Carroll, Meyer et al. 2006). 
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GSE11352: MCF-7 cells were grown to 80% confluence in D-MEM/F-12 
supplemented with 10% FBS. Cells were switched to phenol red-free D-MEM/F-12 medium 
supplemented with 0.5% charcoal-dextran stripped FBS for 24 h before the 10nM 17β-
estradiol (E2) was provided for 12, 24 and 48 hours in a time-course treatment (Lin, Vega et 
al. 2007). 
GSE8597: MCF-7 breast carcinoma cells were maintained in a-minimal Eagle’s 
medium (a-MEM) supplemented with 10% fetal bovine serum (FBS). Before the treatment, 
cells were grown in phenol red-free Dulbecco’s modiﬁed Eagle’s medium (DMEM) 
containing 10% charcoal-treated FBS, 1% sodium pyruvate, 1% penicillin/streptomycin and 
1%L-glutamine for 3 days. The day before hormonal stimulation, the medium was switched 
to phenol red-free DMEM supplemented with 0.5% charcoal-treated FBS. Pretreatments 
cycloheximide (10 mg/ml, Sigma) were started 1 h before hormonal treatment with/without 
17b-estradiol (E2, 25 nM, Sigma), or vehicle (0.1% ethanol). Treatments were done for 24 
hours (Bourdeau, Deschenes et al. 2008). 
GSE11467: MCF-7 cells were treated with 10 nM E2, 10 ng/ml TNFa, or both for 2h. 
Before analysis, the TNF-α with/without E2 treated samples were eliminated. E2 treated and 
control samples were used (Frasor 2008). 
GSE5840: Establishment of tamoxifen-(OHT-resistant-MCF7) and fulvestrant-(ICI-
resistant MCF7) resistant sublines: Three different media were used: a growth medium, a 
hormone-free medium, and a basal medium. Figure 2.4.1 shows how to establish these 
sublines. Wild-type MCF7 cells maintain were in the growth medium. OHT- resistant MCF7 
cells were maintained in hormone-free medium supplemented with 10
-7 
mol/L OHT to 
establish the tamoxifen-resistant subline, designated as MCF7-T. Finally, ICI-resistant cells 
were maintained in the hormone-free medium supplemented with 10
-7 
mol/L fulvestrant to 
establish the resistant subline, namely MCF7-F. Cells were continuously cultured under these 
conditions for 12 months (Fan, Yan et al. 2006). 
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Figure 2.4.1. Establishment of OHT-resistant, ICI-resistant MCF7 cells and maintenance of 
wild-type MCF7 cells (Fan, Yan et al. 2006). 
 
GSE10879: Wild-type MCF7 cell and long-term estrogen deprived MCF-7:5C and 
MCF-7:2A breast cancer cells lines (which are resistant to estrogen-deprivation; aromatase 
inhibitor resistant) were used. These cells were grown in estrogen-free media (phenol red-
free RPMI medium supplemented with 10% 4X dextran-coated charcoal-treated fetal bovine 
serum) until they were 70-80% confluent. In the result part, more information about 
MCF7:5C and MCF7:2A will be given (Lewis-Wambi, Cunliffe et al. 2008). 
 
2.4.4. Microarray analysis:  
 
GEO datasets to be used in the study were divided into two groups, one dealing with 
cell line studies, the other with primary human breast tumors (Tables above, Table 2.4.1.1 
and 2.4.1.2). Furthermore, the datasets were normalized with RMA using BRB-tool which 
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uses Bioconductor R packages when raw .cel files were available, if unavailable, the series 
matrix files were used and global median normalization was performed over the normalized 
data for each GSM, separately.  
 
2.4.5. Analysis of Data:  
 
After the normalization step, class comparison analysis with random variance was 
performed by using the BRB-tool (Simon, Lam et al. 2007) and the expression value of 
CHRNA5 was exported from BRB Array Tools. In in vitro studies, student’s t tests were 
used to calculate the level of differential expression at each treatment relative to the control. 
In addition, one-way ANOVA and Fisher’s exact test was applied to suitable datasets 
(Minitab 15). On the other hand, in breast cancer tumor studies, first, box-plots of samples 
were performed to determine the outliers with expression values greater than 1.5 times the 
interquartile range (IQR) away from the top or bottom of the box. In general, the fold-change 
was not higher than 1.5 but outliers were 2-4 fold higher expression than the control 
conditions. Therefore, the outliers were eliminated. Then, a t-test was used to calculate the 
level of differential expression at each condition relative to the control condition. In ER 
status studies (GSE3494, GSE5460, GSE2034, GSE6532 and GSE4922), the mean value of 
ER+ samples was assumed as control samples, mean value was equalized to one and the fold-
change difference was calculated. In grade, studies involving grade with ER status, and the 
therapy status, grade 1, ER+ grade 1 and untreated (ER+) grade 1 were assumed as the 
control samples and a similar method in ER+ study was used to find the fold changes. 
 
2.4.6. Regression Analysis:  
 
Regression analysis is a commonly used statistical tool to explore the relationships 
between variables. In our analysis, to determine the dose and time effects of estrogen, 
regression analysis of GSE4668, GSE11324 and GSE11352 was performed. GSE4668 was 
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divided into two groups i.e., dose-dependent and time-dependent hormone starvation. 
Polynomial regression analysis was performed via Minitab 15 for these data analyses. On the 
other hand, linear regression analysis was performed for GSE11324 and GSE11352 datasets. 
 
2.4.7. Analysis of Co-expressed Genes: 
 
Probesets correlated positively or negatively with CHRNA5 at r = 0.7 were identified 
from GSE8597, GSE11352, GSE11324, GSE11791, GSE4668 and GSE5840, individually. 
GSE3529 and GSE11467 were not involved in these analysis because GSE3529 consisted of 
three different cell lines and CHRNA5 was not altered in GSE11467 due to the short-time 
estrogen exposure. After correlation analysis, the common probes were determined from 
these data via BRB ArrayTool intersect genelist objectives. After determining the correlated 
genes, GO analysis and pathway analysis were performed using Webgstalt. On the other 
hand, Binary Tree class prediction analysis was performed via K-nearest neighbours (k= 3) 
method, under p<0.05 to investigate the prediction ability of this genelist in terms of ER 
status and grade status. 
 
2.5. Statistical Analysis of Cell Proliferation: 
In MTT assay, the significance of each treatment compared with the control was 
calculated with ANOVA followed by Fisher’s Multiple Comparisons (Minitab 15). 
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CHAPTER 3: AIMS AND STRATEGY 
 
Breast cancers commonly occur in women from multiple genetic and sporadic 
backgrounds. Recent high-throughput studies revealed that the disease is heterogeneous, and 
is associated with multiple risk factors one of which is smoking. However, the association 
between smoking and breast cancer is not investigated in detail; furthermore it is 
controversial. On the other hand, recent studies implicated nicotine, an agonist of nicotinic 
acetylcholine receptors, with increased proliferation, anti-apoptosis, angiogenesis, and 
metastasis, yet mostly in lung cancers. Recent studies also focus on gene expression profiling 
of these cholinergic receptors, as well as on mechanisms through with the receptors act on 
signaling pathways, including PI, MAPK, RAF1, and others. Most recently, CHRNA5, the 
nicotinic acetylcholine subunit alpha 5 have been associated with nicotine addiction as well 
as cancer development and became the focus in the field. However, the molecular effects of 
nicotine on breast cancer cells under starvation or the expression of cholinergic receptors 
and/or association of these with breast cancer are not clear or well studied to our knowledge. 
Microarray technologies allow for characterization of the whole transcriptome under specific 
treatments and conditions. Nicotine treatment has been studied in the context of neuronal cell 
line and bronchial epithelial cells, however, breast cancer cell lines have not been studied in 
this context; and we do not have any insight into the global regulation of transcription in 
breast cancer cells when exposed to physiological concentrations of nicotine (in the range of 
90nM-1μM). 
Accordingly, our aim was to determine the proliferation and apoptotic response to 
different doses of nicotine at different exposure times using cellular assays and molecular 
markers. We also induced serum starvation stress to assess whether nicotine exposure was 
able to rescue cells from growth arrest/apoptosis. Furthermore, we used microarrays to 
profile expression under 1 uM nicotine treatment with or without serum to identify a set of 
differentially expressed genes and to characterize generalized pathways involved in 
nicotine’s effects on MCF7 breast cancer cells. Furthermore, we performed a large scale 
meta-analysis of existing publicly available microarray datasets (in vitro and in vivo) 
obtained from GEO, to assess the involvement of estrogen, estrogen receptor status, and 
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estrogen signaling on expression of CHRNA5, a gene recently identified as important in 
nicotine addiction and lung cancer. Our aim was to predict the estrogen receptor and grade 
status of primary breast tumors using CHRNA5 and its correlated partners, as the candidate 
gene-list.  
In summary, in the present thesis, I have tried to answer the following questions using 
cell culture, microarray technology, statistics, and meta-analysis methods: 
1) Does nicotine dose- and time-dependently affect MCF7 cell line proliferative and 
apoptotic status? 
2) What is the extent of transcriptional modulation by 1 μM nicotine for 2 days at 
10% and 0.1% serum conditions? 
3) What signaling pathways and Gene Ontologies, the differentially expressed genes 
belong to for giving insights into further research with nicotine on breast cancers? 
4) Is CHRNA5 expressed in ER+ and ER- breast cancer cell lines and tumors 
differentially? 
5) Is tamoxifen effective on CHRNA5 expression? 
6) Is CHRNA5 expressed in Grade I, Grade II, and Grade III breast tumors, 
differentially? 
7) Do CHRNA5 and its correlated gene set module obtained from in vitro microarray 
studies accurately predict primary tumor ER and Grade status? 
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CHAPTER 4: RESULTS 
4.1. Nicotine-mediated Signaling Pathways via Microarray Experiments in MCF7 Cell 
Line 
4.1.1. The dose-and time-dependent effect of nicotine on breast cancer cell 
proliferation: 
 
 
Nicotine promotes the cell growth in different cancers such as lung, gastric and colon 
cancer (Heeschen, Jang et al. 2001; Trombino, Cesario et al. 2004; Ye, Liu et al. 2004; Shin 
and Cho 2005). To investigate the effect of nicotine on breast cancer cells, we treated the 
MCF7 cells with different doses of nicotine for different periods of exposure times: 0.1, 1 
and 10 μM for 2, 3, 5 and 7 days. Each MTT assay was performed once or twice and a 
representative set was shown in Figure 4.1.1 for each condition. We showed that nicotine did 
not promote the MCF7 cells proliferation/growth in a either dose-dependent or time-
dependent manner in the presence of 10% serum although 3 days treatment exhibited a 
slightly significant decrease. 
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Figure 4.1.1. Time- and dose-dependent effects of nicotine treatment on MCF7 cell 
proliferation/growth at 10% serum. MCF7 cells were treated with different dose of nicotine: 
0.1, 1 and 10 μM for 2, 3, 5 or 7 days. A) 2 days; B) 3 days; C) 5 days; D) 7 days. * indicates 
p<0.05 determined by one-way ANOVA.  
 
In complete media condition, nicotine may not assert its growth promotion. Therefore, 
to further examine growth promotion effect, MCF7 cells were treated with nicotine under 
serum-starved conditions (0.1% serum in medium) in same doses and for the same periods. 
Each MTT assay was performed once or twice and results in the Figure 4.1.2.A, B and C 
included a representative set. On the other hand, due to the high variability in one of the day 
7 experiment sets, the set demonstrating significance at 1μM nicotine treatment was shown 
(Figure 4.1.2.D). Like before, as in the Figure 4.1.2 A and B, either 2 days or 3 days 
treatment with nicotine did not induce cell growth. On the other hand, at day 5 (Fig. 4.1.2 C), 
nicotine significantly increased the cell growth at all doses, similarly. At day 7, nicotine 
significantly increased cell growth at 1 μM concentration (Fig. 4.1.2 D). These results 
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indicated that under serum starvation conditions, nicotine may induce the cell 
proliferation/growth at 5 days and to a lesser degree at 7 days. 
 
 
Figure 4.1.2. Time- and dose-dependent effects of nicotine treatment on MCF7 cell 
proliferation/growth at 0.1% serum. MCF7 cells were treated with different dose of nicotine: 
0.1, 1 and 10 μM for 2, 3, 5 or 7 days. A) 2 days; B) 3 days; C) 5 days; D) 7 days. * indicates 
p<0.05 determined one-way ANOVA. 
 
4.1.2. Nicotine modulates Cyclin E protein expression in a serum-dependent 
manner: 
 
Serum starvation leads to cell cycle arrest whereas nicotine is known to promote the 
cell cycle leading to cell proliferation (Dasgupta, Rastogi et al. 2006). Therefore, cells were 
treated with 1 μM nicotine under 10% serum or 0.1% serum conditions and the protein levels 
of cyclin E levels, an important regulator of cell cycle progression, were measured using 
Western blotting. 
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Figure 4.1.3.Cyclin E expression in response to nicotine treatment under different serum 
conditions. MCF7 cells were treated with 1 μM nicotine treatment under different serum 
conditions for 2 days and calnexin was used as a loading control. 
 
Nicotine reduced the cyclin E levels at 10% serum treatment but led to an increase at 
0.1% serum levels (Fig. 4.1.3). 
4.1.3. Nicotine modulates p53 and Bcl-xl protein levels in a serum-dependent 
manner: 
 
In addition to nicotine’s proliferative effect, nicotine also is known to lead to resistance 
to apoptotic stimuli (Dasgupta, Kinkade et al. 2006). Serum starvation on the other hand, may 
result in apoptosis. Dasgupta et al. showed that nicotine inhibited the induction of p53 upon 
chemotherapeutic drug stimulation (Dasgupta, Kinkade et al. 2006). In addition, Bcl-xl, a 
known member of the anti-apoptotic Bcl-2 family, might indicate the status of apoptosis in 
serum starved nicotine treated cells. Therefore, to examine the effect of nicotine upon serum 
withdrawal induced apoptosis in MCF7 cells, cells were treated with 1 μM nicotine in 10% 
serum or 0.1% serum conditions for 2 days; and the protein level of p53 and Bcl-xl were 
measured. Serum starvation led to p53 induction and nicotine slightly reduced the protein 
level of p53 (Fig. 4.1.4A). On the other hand, nicotine induced Bcl-xl at both serum 
conditions even though the induction was slightly higher than untreated cell grown under 
0.1% serum (Figure 4.1.4B). Taken together, these results indicated that nicotine might 
inhibit the serum withdrawal induced apoptosis. 
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Figure 4.1.4. The anti-apoptotic effects of nicotine under different serum conditions. A) p53 
B) Bcl-xl. MCF7 cells were treated with 1 μM nicotine treatment under different serum 
conditions for 2 days and calnexin was used as a loading control. 
 
4.1.4. Genome-wide profiling of nicotine exposure in MCF7 cells: 
 
It was observed that 1 μM nicotine treatment was statistically significant at both the 5 
days and 7 days treatment for recovery of the cell growth (Fig 4.1.2 C and D). Furthermore, 
reports indicated that 1μM nicotine closely mimics the physiological concentration of 
nicotine in the blood of smokers (Chu, Guo et al. 2005). Accordingly, 1 μM nicotine was 
chosen as the dose to profile expression in MCF7. In addition, we wanted to examine the 
relatively early effects of nicotine in breast cancer. Accordingly, medium supplemented with 
10% serum as physiological conditions and the media supplemented with 0.1% serum as 
serum-starved conditions were studied with or without nicotine exposure for 2 days. 
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4.1.5. RNA and Microarray data quality assessment: 
 
Testing of the purity and integrity of the RNA is the most crucial step to obtain high 
quality microarray datasets. Therefore, RIN (RNA integrity number) values of samples were 
measured using BioAnalyzer before microarrays were hybridized (Fig. 4.1.5).  
 
Figure 4.1.5. RNA integrity graphs of microarray samples. A and B represent samples 
grown in media with 0.1% serum. C, D, E, and F represent samples grown in media 
supplemented with 10% serum. A, C and E are the control samples whereas B, D and F are 
the 1μM nicotine treated samples. 
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Table 4.1.1. Description table of the microarray samples and RIN values. 
 
According to the graphs, RIN values obtained ranged between 9.0 and 9.6 indicating 
high quality RNA samples (Table 4.1.1). Apart from the pre-hybridization RNA quality, 
post-hybridization quality also is important. BRB-Array tool allows for assessment of the 
correspondence between the samples after hybridization. The RNA samples described in 
Table 4.1.1 all had comparable RNA degradation profiles, and other parameters that help 
identify sample outliers, such as background, scaling factor, housekeeping 3’/5’ ratios. 
The blue horizontal lines in Figure 4.1.6 represented the scale factor. If the scaled 
factors were out of range, horizontal lines became red. The blue circles and blue triangle 
points represented GAPDH and B actin 5’/3’ ratios, respectively. Like the scale factor, if 
these values fell out of range, they were marked with red color. Our findings indicated that 
GAPDH and B-actin ratios and scale factors of the RNA samples were all within range, and 
microarray data were good quality (Table 4.1.2).  
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Figure 4.1.6. Quality control plots of microarray samples. The order of the samples from top 
to bottom. A) R6-Konu and R5-Konu B) R8-Konu, R7-Konu C) R9-Konu, R10-Konu (see 
Table 4.1.1 for descriptions). 
Table 4.1.2. Data associated with Figure 4.1.6. 
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Figure 4.1.7. RNA degradation plots of microarray experiments. A) R5-R6 B) R7-8  
C) R9-R10 
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RNA degradation graphs indicated that all samples had similar slopes (Fig. 4.1.7) 
indicating they were comparable. Accordingly, all these data demonstrated that microarray 
experiments were highly qualified for further data analysis. 
 
4.1.6. Nicotine’s effect on MCF7 transcriptome under the physiological serum 
conditions: 
 
To examine the acute effects of nicotine in 10% serum treated MCF7 cells, we 
performed microarray experiment with RNA samples obtained from MCF7 cells treated with 
1 μM nicotine for 2 days. Before determining the differentially expressed genes, whole 
genome expression was visualized using a scatter plot between control and nicotine-treated 
samples (2 replicates, each) in order to visualize the expression changes at the global level 
with a threshold of 2-fold change (Figure 4.1.8). Our findings indicated that there were very 
few number of probesets with altered expressions greater than 2 fold suggesting that 
nicotine’s effects at the given concentration is mild.  
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Figure 4.1.8. Scatter plot of probesets with or without nicotine treatment in 10% serum 
conditions. 
 
A 1.2 fold change cut-off was used to determine the differentially expressed genes since 
nicotine altered gene expression to a limited degree. To associate probesets above the 
threshold with significance between group means, a class comparison analysis was performed 
yielding 1345 probesets. GO (Gene Ontology) analysis performed using the WebsGestalt 
bioinformatics tools helped characterize the functional effect of nicotine effect on whole 
genome. In Figure 4.1.9, overrepresented biological processes or molecular functions that 
were shown in red color were obtained based on hypergeometric tests implicating functions 
potentially altered by nicotine treatment. Accordingly, nicotine altered different biological 
functions such as cell adhesion, cell growth, cell death, cell proliferation and differentiation 
which are also important processes for cancer development. In addition, Figure 4.1.9B 
indicated that nicotine regulated DNA binding, enzyme binding, correpressor activity and 
protein dimerization activities.  
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Apart from the functional analysis, KEGG and Biocarta pathway analyses were 
performed to detect nicotine’s effect on signaling pathways. Again, WebGestalt 
bioinformatics tools and hypergeometric tests were used to find the significant pathways. The 
significant pathways were represented in Table 4.1.3.  
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Figure 4.1.9. GO analysis of nicotine treatment in 10% serum. A) Biological process analysis; 
B) Molecular function analysis. Functions shown in red color indicated significant at p<0.05 in 
terms of hypergeometric test. 
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Table 4.1.3. Pathway analysis of nicotine treatment in 10% serum 
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.  
Phosphatases in MAPKinase pathway and caspase cascade activity in apoptosis from 
the Biocarta pathway analysis, and the focal adhesion and colorectal cancer pathway in the 
KEGG pathway analysis were the most interesting functional groups. These pathways play 
key roles in cancer, and some of which have been previously been associated with nicotine 
exposure. Thus, these results demonstrated that nicotine might alter the gene expression, 
although through mild changes in genes that have a role in cancer development. 
 
4.1.7. Preliminary analyses of MCF7 transcriptome under serum starvation and 
nicotine treatment: 
 
 
MTT assays indicated that nicotine promoted the growth of MCF7 cells under serum-
starved conditions. Therefore, we decided to assess the acute effect of nicotine on MCF7 
cells in serum-starved conditions, i.e., 0.1% FBS with or without 1 μM nicotine treated for 2 
days. 
Scatter plot analysis of nicotine treated samples in comparison with control samples 
under 0.1% serum starvation conditions provided a generalized information on the extent of 
modulation under the treatment conditions. Similar to experiments in 10% serum condition, a 
small number of probesets exhibited more than 2-fold changes; yet the magnitude of 
modulation was greater than the experiments performed with 10% serum (Figure 4.1.10). 
Since there was only one replica for each experiment in 0.1% serum control and nicotine 
groups, a 1.5 fold-change was used to find a potential set of differentially expressed 
probesets in response to nicotine treatment under serum starvation. Based on this filtering 
criterion, there were 630 probesets that were altered in response to 1 μM nicotine. GO 
analysis via WebGestalt bioinformatics tools was performed to identify biological processes 
altered in response to treatment (Figure 4.1.11). 
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Figure 4.1.10. Scatter plot of probesets with or without nicotine treatment in 0.1% serum 
conditions. 
 
Figure 4.1.11A indicated that probesets functioning in notch signaling, protein kinase 
pathway, stress activated protein kinase signaling pathway, positive regulation of signal 
transduction, regulation of IκB kinase/ NFκB cascade, apoptosis, regulation of program cell 
death, negative regulation of progression through cell cycle and others were significantly 
altered by nicotine treatment under serum starvation. These genes had different molecular 
functions such as magnesium binding, tubulin binding, phosphatase binding, SH3 domain 
binding, phosphotransferase activity, amino-acid polyamine transpoter activity and others 
(Fig. 4.1.11B).  
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Figure 4.1.11. GO analysis of nicotine treatment in 0.1% serum. A) Biological processes; B) 
Molecular function. Functions shown in red color indicated significance at p<0.05 in terms of 
hypergeometric test  
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Table 4.1.4. Pathway analysis of nicotine treatment in 0.1% serum 
.  
Biocarta and KEGG pathway analyses indicated that nicotine influenced the expression 
of genes functioning particularly in the apoptosis pathway. In addition to apoptosis, focal 
adhesion, tight junction, MAPK signaling pathway, insulin signaling pathway, Wnt signaling 
pathway, chronic myeoid leukemia, glioma and colorectal cancer pathways were found 
significant (Table 4.1.4). Thus, these results indicated that nicotine altered the gene 
expression related to cancer also under serum starvation. 
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4.1.7.1. Nicotine treatment under starvation might lead to recovery of cell 
expression in a subset of probesets: 
 
 
Many studies showed the proliferative and anti-apoptotic effect of nicotine in different 
cancers (Egleton, Brown et al. 2008). Cells grown under serum starvation were known to be 
under stress and might induce cell-stress mechanisms such as apoptosis. Since nicotine had 
anti-apoptotic effects, we expected that nicotine treated cells grown under serum limiting 
conditions might behave as cells grown in physiological serum conditions. Therefore, 
nicotine treated and untreated cells grown in 0.1% serum were compared to untreated cells 
grown in 10% serum. 
 
630 probes were found in the 0.1% serum treatment data that changed 1.5 fold with 
respect to control cells grown under the same conditions. These probes were divided into two 
groups according to the relationships between 0.1% nicotine and 10% serum control 
conditions, as it was mentioned in materials and methods. Accordingly, 404 probes were 
identified as probesets behaving similar to probesets from the 10% serum. Genes functioning 
in notch signaling, protein kinase pathway, stress activated protein kinase signaling pathway, 
positive regulation of signal transduction, regulation of IκB kinase/ NFκB cascade, apoptosis, 
regulation of program cell death, negative regulation of progression through cell cycle and 
others were identified as significantly modulated (Figure 4.1.12). These genes had diverse 
molecular functions such as magnesium ion binding, insulin-like growth factor binding, 
kinase activity, phosphotransferase activity, nucleotide receptor activity and so on (Figure 
4.1.12). 
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Table 4.1.5. Pathway analysis of genes which nicotine treated cells in 0.1% serum had 
similar response to untreated cells in 10% serum. 
 
  
Biocarta analyses showed nicotine’s effect on caspase cascade in apoptosis, role of 
mitochondria in apoptotic signaling, regulation of BAD phosphorylation and Erk1/Erk2 
MAPK signaling. In addition to MAPK signaling pathway, KEGG pathway analysis 
indicated the effect of nicotine in focal adhesion, Wnt signaling pathway, insulin signaling 
pathway, colorectal cancer and others (Table 4.1.5). 
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Figure 4.1.12. GO analysis of genes which nicotine treated cells in 0.1% serum had similar 
response to untreated cells in 10% serum. A) Biological processes B) Molecular function. 
Functions shown in red color indicated significance at p<0.05 in terms of hypergeometric 
test. 
B 
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Besides GO analysis and pathway analysis, cluster analysis was performed whether 
nicotine treated cells in 0.1% serum and untreated cells in 10% serum were clustered 
together. Since untreated cells in 10% serum had two replicas and others had only one, the 
mean value of untreated cells in 10% serum was calculated and used for cluster analysis. 
Nicotine treated cells in 0.1% serum and untreated cells in 10% serum were clustered 
together (Figure 4.1.13).  
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Figure 4.1.13. Cluster analysis of genes which nicotine treated cells in 0.1% serum had 
similar response to untreated cells in 10% serum A) Up-regulated genes in nicotine 
treatment. B) Down-regulated genes in nicotine treatment. Partial representations. 
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All together 404 probesets behaved similarly as they were exposed to physiological 
serum conditions. In conclusion, nicotine treatment regulated genes functioning in apoptosis 
suggesting nicotine might help rescue the cells from serum-starvation stress. In addition, 
nicotine altered genes functioning in regulation of progression through cell cycle and MAPK 
signaling pathway may lead to cell cycle progression under serum starvation.  
 
4.1.7.2. Nicotine modulates expression independent of serum starvation for a 
subset of probesets: 
 
Probesets behaving inverse to those of untreated 10% serum grown MCF7 cells were 
226; when compared with 404 probesets behaving similarly this is much less. GO analysis 
showed that genes with roles in carboxylic acid transport, organic acid transport and protein 
complex assembly. Furthermore, these genes had translation initiation factor activity and 
kinase activity as significantly altered molecular functions (Figure 4.1.14). On the other 
hand, Biocarta and KEGG pathway analysis showed that regulation of transcriptional 
activity, HIV-1Nef: negative factor of FAS and TNF, FAS signaling pathway, tight junction, 
VEGF signaling pathway, Histine metabolism, glioma, pancreatic cancer and chronic 
myeloid leukemia and others were modulated by nicotine treatment (Table 4.1.6). 
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Table 4.1.6. Pathway analysis of genes inversely correlated between 0.1% serum-nicotine 
and 10% serum samples. 
 
 
Cluster analysis showed that serum-starved samples were clustered together and 
separated from untreated cells in 10% serum (Figure 4.1.15). Although these probesets 
clustered together with 0.1% serum control treatment, the effect of nicotine was more 
prominent.  
86 
 
 
A 
87 
 
 
Figure 4.1.14. GO analysis of probesets inversely correlated between 0.1% serum-nicotine 
and 10% serum samples. A) Biological processes B) Molecular function. Functions shown in 
red color indicated significance at p<0.05 in terms of hypergeometric test  
B 
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Figure 4.1.15. Cluster analysis of probesets inversely correlated between 0.1% serum-
nicotine and 10% serum samples. A) Up-regulated genes in nicotine treatment. B) Down-
regulated genes in nicotine treatment. 
89 
 
 
 
 
4.1.8. Cholinergic nAChR receptor expression analysis: 
 
 
Nicotine asserts its function via binding to nicotinic acetylcholine receptors. This led us 
to examine the effects of nicotine on cholinergic receptor expression. After normalization, 
the cholinergic receptor expressions were extracted. Cluster analysis was performed and the 
results were visualized via Java Treeview program. Nicotine did not alter the cholinergic 
receptor expression at the concentrations and time-courses examined in the present study 
(Figure 4.1.16). 
90 
 
 
 
Figure 4.1.16. Cluster analysis of nAChRs  in respose to nicotine treatment at different 
serum conditions. 
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Table 4.1.7. Results of class comparison analysis of nAChRs under 10 % serum conditions.  
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Table 4.1.8. Results of fold-change of nAChRs under serum starvation 
 
.  
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To further understand the effects of nicotine on receptor expression, samples were 
divided into two groups with respect to serum conditions and class comparison analysis was 
performed for 10% serum conditions (Tables 4.1.7 and 4.1.8, for 0.1% and 10% serum, 
respectively). As in the Table 4.1.7, only the expression of CHRNA4 genes was significantly 
altered by nicotine and nicotine decreased the expression according to class comparison 
result. However, the fold change was less than 1.2. On the other hand, expression of 
CHRNA6, CHRNA3, and CHRNB1 were altered by nicotine under serum starvation but the 
significance of these alterations were unknown due to presence of only one replica and very 
slight changes (Table 4.1.8). 
 
On the other hand, our findings suggested that (Figure 4.1.16) serum condition strongly 
influenced the clustering of the samples although this finding should be confirmed with 
analysis of additional samples. The expression of CHRNA5, CHRNA10 was lower under 
serum starvation while CHRNAB1 had higher expression in terms of fold change with 
respect to 10% FBS conditions (Table 4.1.9), Specifically, CHRNA5 expression was 
decreased about 2 fold under serum starvation. 
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Table 4.1.9. Results of fold-change of nAChRs between serum starvation and physiological 
serum concentrations. 
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4.2. Involvement of Estrogen in CHRNA5 Signaling: 
 
In this section, we have performed a meta-analysis of CHRNA5 expression using 
microarray datasets obtained from in vitro and and in vivo breast cancer experiments 
deposited in the public expression study database GEO. 
 
4.2.1. CHRNA5 Expression Analysis in Breast Cancer Cell Lines: 
 
 
Before the detailed analysis, class comparison analysis of in vitro studies was 
performed via BRB ArrayTool. The p-values and FDR values were represented in Table 
4.2.1, such that CHRNA5 expression was significantly altered in each condition except 
GSE11467. The reason for the insignificance of GSE11467 will be mentioned in the future 
paragraphs. 
 
Table 4.2.1. Class comparison results of in vitro studies.  
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4.2.1.1. Estrogen treatment increases CHRNA5 expression: 
 
 
It is observed that MCF7 breast carcinoma cells were widely used to study estrogen 
signaling pathway because MCF7 cells were characterized as ER-α positive breast cancer 
cells and their growth depends on estrogen (Bourdeau, Deschenes et al. 2008). Moreover, 
MCF7 cell lines have different sublines exhibiting different responses to estrogen; for 
example, estrogen-independent MCF7:2A and highly-sensitive MCF7/BUS cells. 
To assess the effects of estrogen treatment on CHRNA5 expression, microarray data 
sets GSE3529 and GSE11791were used. In GSE3529 Rea et al. used three different ER-α 
positive cell lines: MCF7, T47D, and BT-474 (Rae, Johnson et al. 2005). Biological 
duplicates of each cell line were grown in the presence or absence of estrogen for 24 hours. 
When the untransformed expression values were compared (Fig. 4.2.1A), we found that 
CHRNA5 expression was significantly different in each cells suggesting variability across 
individuals. The range of the expression was between 100 and 600 units, T47D exhibiting the 
highest expression of all three cell lines. Effect of E2 treatment with respect to control was 
calculated as fold change. As shown in the figure 4.2.1B, there was no significant change in 
BT-474 cells whereas estrogen-induced increases in CHRNA5 expression were observable in 
the T47-D and MCF7 cells although the only the change in MCF7 cells was statistically 
significant (p<0.05). 
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Figure 4.2.1. Estrogen effect on CHRNA5 expression in the data set GSE3529 (Rae, Johnson 
et al. 2005) using BT474, T47D and MCF7 cell lines. A) Absolute expression value of the 
probeset 206533_at B) Fold change differences between the control and E2 treated cells. * 
indicates p <0.05 determined by student’s t-test. 
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To validate the estrogen effect on CHRNA5 expression, GSE11791 performed by 
Musgrove et al. also was analyzed. In this study, each experimental group had three 
biological replicates while MCF7 cells were treated with 100 nM estrogen for 6 hours 
(Musgrove, Sergio et al. 2008). Similarly, our results indicated that estrogen had a 
significantly positive effect on CHRNA5 expression, which is likely to be cell-type 
dependent (Figure 4.2.2).  
 
Figure 4.2.2. CHRNA5 expression in response to E2. In GSE11791 (Musgrove, Sergio et al. 
2008), MCF7 cells were treated with 100 nM estrogen for 6 hours. * indicates the p < 0.05 
determined by student’s t-test 
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4.2.1.2. Estrogen induces the expression of CHRNA5 in a dose- and time-
dependent manner:  
 
To further examine the effects of estrogen treatment on CHRNA5 expression, we 
analyzed three independent microarray datasets designed to determine dose- and time-
dependent effect of estrogen (GSE4668, GSE11324 and GSE11352). Before analyzing the 
expression of CHRNA5, pS2 expression analysis performed as a positive control for estrogen 
treatment (Appendix A, Figure 6.1). 
 
GSE4668 conducted by Coser et al. was designed to assess the dose-response and time-
course hormone starvation effect using MCF7/BUS. MCF7/BUS cells showed higher 
proliferative response to estradiol-17 beta then MCF7 from ATCC and responded to as low as 
2 pM estrogen with a reproducible estrogen dose-dependent growth curve (Coser, Chesnes et 
al. 2003). In addition, in the absence of estrogen, MCF7/BUS cells blocked proliferation and 
became arrested in the G0/G1 phase of the cell cycle (Villalobos, Olea et al. 1995). Pure anti-
estrogen treatment fully blocked the estrogen growth-stimulating affect meaning that estrogen 
induced the cells via estrogen receptor (Coser, Chesnes et al. 2003). Furthermore, western 
blot experiments showed only the presence of ER-α but not the presence of ER-β in these 
cells (Coser, Chesnes et al. 2003). Thus, the MCF7/ BUS breast cancer cells represent one of 
the best models to study the estrogen signaling via estrogen -ER-α interaction. 
 
As mentioned above, Coser et al. treated the MCF7/BUS cells with 0, 10, 30, 60, and 
100 pM estrogen for 48 hours (Coser, Chesnes et al. 2003). It also was shown that beyond 
100pM, these cells did not respond to estrogen. As shown in the Figure 4.2.3, CHRNA5 
expression was enhanced with increasing E2 concentrations. Interestingly, the polynomial 
regression analysis (Table 4.2.2) indicated that a linear increase in expression up to 30 pM 
was apparent whereas greater than 30pM of E2 resulted in an asymptotical response.
 
100 
 
 
Figure 4.2.3. CHRNA5 expression to estrogen dose-dependent treatment. In GSE4668 
(Coser, Chesnes et al. 2003), MCF7/BUS cells was treated with different dose of estrogen: 0, 
10, 30, 60 and 100 pM for 48h. * indicates significant in the crease CHRNA5 expression to 
these doses and p<0.001 calculated by one-way ANOVA.
 
To further characterize the estrogen effect, Coser et al. performed hormone-starvation 
experiment with an expectation of suppression of the estrogen induced genes in the previous 
induction study (Coser, Chesnes et al. 2003). CHRNA5 expression decreased in MCF7/BUS 
cells exposed to hormone starvation for 0, 1 or 2 days in a time-dependent manner (Figure 
4.2.4), with a similar profile as observed in Figure 4.2.3. These results suggested that 
estrogen induced the CHRNA5 expression dose-dependently, and CHRNA5 expression was 
repressed by hormone starvation in a time-dependent manner. Polynomial regression analysis 
(Table 4.2.2) indicated that hormone starvation reduced the expression of CHRNA5 in a 
time-dependent manner. Both studies exhibited a similar leveling off above concentrations 
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greater than 30pM suggesting a non-linear response, which may be related with the saturation 
of receptor signaling or availability of the CHRNA5 inherent response to estrogen. 
 
 
Figure 4.2.4. CHRNA5 expression in response to hormone starvation. In GSE4668 (Coser, 
Chesnes et al. 2003), MCF7/BUS cells were treated with hormone starved medium for 0, 1, 
and 2 days. * indicates significant the reduction of CHRNA5 expression and p<0.001 
calculated by one-way ANOVA. 
 
Similarly in another time-series study (GSE11324) (Carroll, Meyer et al. 2006) MCF7 
cells were stimulated with 100 nM estrogen for 0, 3, 6, or 12 hours and all experiments were 
performed in triplicate. Figure 4.2.5A indicated that CHRNA5 expression was enhanced with 
increasing time in the presence of estrogen treatment. 3 hr estrogen treatment did not 
significantly induce the CHRNA5 expression whereas 6 hr and 12 hr inductions were 
statistically significant. Again, a similar leveling off affect was observed suggesting 
saturation of the response. 
102 
 
 
Table 4.2.2. Regression analysis of dose-dependent and time-dependent data.  
 
 
On the other hand, a third time-course studies (GSE11352; Lin, Vega et al. 2007), in 
which MCF7 cells were investigated for 12, 24 and 48 hours, in the presence or absence of 
E2 treatment. CHRNA5 expression increased at all the time point regardless of treatment 
condition (Fig. 4.2.5B). However estrogen treated samples exhibited higher basal expression 
levels than the untreated samples. Estrogen treatment induced the CHRNA5 expression 
initially at around 20 hours after which leveling off took place almost to the basal levels. This 
suggests that although there is an induction of CHNRA5 expression initially, this response 
may not be maintained over a longer time of exposure and the extent of maintenance might 
vary from experiment to experiment. The different time points and different amount of 
estrogen treatment also might have caused this discrepancy. The first two studies, GSE4668 
and GSE11324, suggested that CHRNA5 expression was induced by estrogen time-
dependent manner and the last study, GSE11352 implies that this induction might reach a 
maximum point and increasing the exposure time may not influence the outcome. Therefore, 
it can be concluded that estrogen induces the CHRNA5 expression in time- dependent 
manner during the short- time exposure. 
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Figure 4.2.5. CHRNA5 expression in response to time-dependent E2 exposure. A) In 
GSE11324 (Carroll, Meyer et al. 2006), MCF7 cells were treated with 100nM E2 for 0, 3, 6 
and 12 h. B) In GSE11352 (Lin, Vega et al. 2007), MCF7 cells were treated with/without 
10nM E2 for 12, 24 and 48 h. * indicates the significant time-dependent response to E2 and 
p<0.001 determined by regression analysis (Table 4.2.2).
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4.2.1.3. CHRNA5 is the secondary target of estrogen signaling: 
 
 
Estrogen regulates gene expression in different ways. Estrogen binding to estrogen 
receptor regulates the expression of primary target genes; in addition to direct binding to 
DNA sequence, estrogen receptors can be recruited the other factors to the DNA sequence or 
regulates the gene expression via non-genomic ways. To further characterize the estrogen 
affect on gene regulations, in the study GSE8597, Bourdeau et al. treated MCF7 cells with 
estrogen in the presence or absence of the translation inhibitor cycloheximide (Bourdeau, 
Deschenes et al. 2008). Then, if estrogen changed the gene expression in the absence of 
cycloheximide but did not affect the gene expression in the presence of cycloheximide, this 
meant that these genes were regulated by estrogen via non-genomic way. In other words, 
such genes needed to have a transcription factor(s) induced by estrogen, translated into 
proteins before regulating expression of target genes. Bourdeau et al. called these genes as 
the secondary targets of estrogen signaling (Bourdeau, Deschenes et al. 2008). In this respect, 
we asked the same question: Is CHRNA5 the primary or secondary target of estrogen 
signaling? Bourdeau et al. found Myc as a primary target and E2F1 as a secondary target 
(Bourdeau, Deschenes et al. 2008). Therefore, in our analysis, Myc and E2F1 were used as 
positive control (Appendix A, Figure 6.2). According to the GSE8597 dataset induction of 
expression in CHRNA5 by estrogen was blocked in the presence of translation inhibitor 
cycloheximide (Fig. 4.2.6).  
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Figure 4.2.6. CHRNA5 expression in response to E2 exposure in the presence or absence of 
translation inhibitor cycloheximide. In GSE8597 (Bourdeau, Deschenes et al. 2008), MCF7 
cells were treated with 25 nM estrogen either in the presence or absence of (25 μg/ml) 
cycloheximide. * indicates p< 10
-7 
determined by one-way ANOVA. 
 
As it is mentioned before, in the figure 4.2.5A, 3 hours estrogen treatment did not 
significantly induce CHRNA5 expression. This supported the idea that CHRNA5 was the 
secondary target of estrogen signaling. To further support this notion, we analyzed the 
GSE11467 performed by Frasor (Frasor 2008; Frasor, Weaver et al. 2008). In this study, the 
authors wanted to examine how E2 and TNF-α together influence gene expression in breast 
cancer cells compared to either factor alone so they treated MCF7 cells with 10nM estrogen, 
10nM TNF-α or both for two hours. We were only interested the estrogen effect so 
eliminated the experiment with 10nM TNF-α or both 10nM TNF-α and estrogen treatment. 
Here, the estrogen induction was done only for 2 hours so if the CHRNA5 were a primary 
target, we expected to see estrogen-induction but otherwise the findings would have 
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supported the theory that CHRNA5 was the secondary target of estrogen signaling. Before 
analysis of CHRNA5 expression, the effect of estrogen in Myc as primary target and E2F1 as 
a secondary target expression was analyzed as a positive control (Appendix A, Figure 6.3) 
(Bourdeau, Deschenes et al. 2008). There was no significant changes in response to estrogen 
in short term E2 exposure (Fig. 4.2.7). In addition to these meta-analysis results of 
microarray expression, we found no putative estrogen receptor binding site on the CHRNA5 
promoter (BrownLab). Thus, all these results indicate that CHRNA5 is the secondary target 
of estrogen.
 
 
Figure 4.2.7. CHRNA5 expression in response to short-time E2 exposure. In GSE11467 
(Frasor 2008), MCF7 cells were treated with 10 nM E2 for 2h. Student’s t-test indicates no 
significance. 
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4.2.1.4. Estrogen-independent MCF7 sublines have higher CHRNA5 
expression: 
 
Hormone therapy is a widely used approach in breast cancer patients. In particular, 
anti-estrogen tamoxifen is used to control the ER activity. Unfortunately, prolonged anti-
estrogen therapy leads to drug resistance in breast cancer patients. In recent years, many 
studies elucidated the anti-estrogen resistance mechanisms. GSE5840 done by Fan et al. was 
the one of the microarray studies to compare the expression pattern of estrogen responsive 
genes in wild-type MCF7, OHT (tamoxifen)–resistant MCF7, and ICI (Fulvestrand)-resistant 
MCF7 cells. The establishment of OHT (tamoxifen) –resistant MCF7 cells and ICI 
(Fulvestrand)-resistant MCF7 cells were mentioned in the material and methods parts (Fan, 
Yan et al. 2006). Accordingly, the difference between anti-estrogen tamoxifen and the pure 
anti-estrogen fulvestrand, is that tamoxifen competitively binds to the ER and leads to an ER 
conformational change, which inhibits ER binding to co-activators and/or make favorable ER 
binding to corepressors as well as it alters ER dimerization and interaction with ERE so the 
genetic estrogen response is blocked (Huang, Norris et al. 2002; Shang and Brown 2002). On 
the other hand, the pure anti-estrogens such as fulvestrand can destroy the ER via binding to 
the newly synthesized estrogen receptor in the cytoplasm and preventing the transportation to 
the nucleus so it prevents estrogen signaling (MacGregor and Jordan 1998; Fan, Yan et al. 
2006). 
As repeatedly shown estrogen induced the CHRNA5 expression in MCF7 cells with 
treatment of 10 nM estrogen for 4 hours, whereas OHT-resistant MCF7 and ICI-resistant 
MCF7 cells were both estrogen-resistant and CHRNA5 expression did not change (Fig. 
4.2.8).  
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Figure 4.2.8. CHRNA5 expression in response to E2 in different MCF7 sublines. In 
GSE5840 (Fan, Yan et al. 2006), MCF7 cells were treated with tamoxifen or fulvestrand for 
12 months to establish OHT-resistant and ICI-resistant MCF7 cell sublines. Then, these 
sublines and wild-type MCF7 cells were treated with 10 nM E2 for 4 h. *indicates p<0.05 
determined by Student’s t-test, each treatment compared with its control. 
 
GSE10879, another study performed by Lewis-Wambi et al. tested whether estrogen-
deprived conditions have an effect on breast cancer cell lines using wild-type MCF-7 cells 
and long-term estrogen deprived MCF-7:5C and MCF-7:2A breast cancer cells (Lewis-
Wambi, Cunliffe et al. 2008). MCF7:5C cells which were obtained after long-term culture in 
estrogen free media were estrogen independent cells. Estrogen treatment did not induce the 
growth of these cells and also anti-estrogen treatment such as tamoxifen and fulvestrand did 
not block any growth. In addition, the level of ER was minor and there was no alteration in 
the affinity of ER for ligand in the cells (Jiang, Wolf et al. 1992). On the other hand, the other 
estrogen-independent cell, the MCF-7:2A grew in the absence of estrogen maximally but 
anti-estrogen such as tamoxifen and fulvestrand inhibited the growth of these cells. In 
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addition, MCF-7:2A cells had high levels of estrogen receptor expression and constitutively 
active ER shown via ER-responsive luciferase reporter construct in the absence of any 
estrogens. Furthermore, tamoxifen and fulvestrand inhibited the ER-responsive luciferase 
reporter construct activation. Therefore, the MCF-7:2A cell represented a good model to use 
in the study of ER action and estrogen-independent growth in human breast cancer cells 
(Pink, Jiang et al. 1995). Thus, MCF7:5C and MCF7:2A cells represent good models for the 
study of the estrogen-deprivation mechanisms. In GSE10879 study where wild-type MCF7, 
MCF7:5C and MCF7:2A cells grown in estrogen-free media CHRNA5 expression was 
compared among the cell lines. MCF7:5C and MCF7:2A exhibited statistically significantly 
higher expression level than wild-type MCF7 cells (Fig. 4.2.9). Therefore, Figures 4.2.8 and 
4.2.9 supported each other and indicated that estrogen-deprivation led to higher CHRNA5 
expression in an estrogen-independent manner.  
 
 
Figure 4.2.9. CHRNA5 expression in estrogen-independent MCF7 clones. In GSE10879 
(Lewis-Wambi, Cunliffe et al. 2008), wild-type MCF7 cells are estrogen-dependent; 
MCF7:5C and MCF7:2A cells are estrogen-independent. * indicates p<0.01. 
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4.2.2. CHRNA5 Expression Analysis in Breast Cancer studies: 
 
To understand further CHRNA5 expression in breast cancer, we collected a set of 
primary tumor datasets for breast cancer from GEO database. Again, to prevent the cross 
platform and different probe affect, studies performed in Affymetrix HG-U133A and HG-
U133 plus2 chips which contain probeset 206533_at. Similar to in vitro studies (Table 4.2.1); 
the class comparison analysis of datasets for each condition was performed as a preliminary 
data. As shown in Table 4.2.3, CHRNA5 was significantly differentially expressed in the 
following conditions. These results leaded us to do further analysis. 
 
Table 4.2.3. Class comparison results of primary breast tumor studies. 
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4.2.2.1. ER status: 
 
Breast cancer cell line studies indicated that estrogen induced the CHRNA5 expression, 
and estrogen-independent cell lines had higher expression levels than wild-type. Therefore, 
we examined whether there was a differential expression between ER+ and ER- breast 
cancers. Since endocrine therapy and tamoxifen targets the ER, we selected breast cancer 
microarray studies from which samples were taken from untreated patients with information 
about the ER status. Statistically, we compared the CHRNA5 expression between the ER+ 
patients and ER- patients; our results indicated that (Fig. 4.2.10) ER- patients had higher 
CHRNA5 expression than ER+ patients. The fold change difference between the ER- and 
ER+ samples was not very high yet was highly significant ( p<0.0005). 
 
 
Figure 4.2.10. CHRNA5 expression based on ER status. ER+ samples were assumed as 
control and equalized to 1. The fold change was calculated relative to ER+. ** and * indicate 
p <0.0005 and p <0.05 determined by student’s t-test. 
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4.2.2.2. Histological Grade: 
 
 
In breast cancer, histological grade is an essential prognostic factor and higher grade 
tumors with ER- status are correlated with higher malignancies (Porter, Evans et al. 2004). In 
addition to this, higher expression of CHRNA5 in ER- breast cancer cells led us to analyze 
the primary breast tumor studies according to histological grade status. In this case, 
microarray studies were divided in two groups such that untreated and treated breast cancer 
samples were separated to prevent heterogeneity caused by therapy. Regardless of therapy, 
CHRNA5 expression was higher in Grade 3 (Fig. 4.2.11). Similar to ER- conditions, the fold 
change difference was not very high yet was very consistant. Grade 1 and Grade 2 tumors did 
not exhibit differences between themselves however Grade 3 CHRNA5 expression was 
higher than either Grade 1 or Grade 2. 
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Figure 4.2.11. CHRNA5 expression based on histological grade level. A) Primary tumor 
from untreated patients B) Primary tumor from treated patients. Grade 1 samples were 
assumed as control and equalized to 1. The fold change was calculated relative to grade1. ** 
and * indicate p<0.005 and p<0.05 determined by student’s t-test, respectively.  
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Since there is a correlation between higher maligancies and Grade 3 with ER- patients 
we analyzed the expression of CHRNA5 with regard to status combining ER and grade. In 
general, ER- patients had higher expression regardless of grade whereas Grade 3 ER- patients 
exhibited the highest expression value in all samples except the grade 1 ER- level due to the 
insufficient number patients (Fig. 4.2.12). 
 
 
Figure 4.2.12. CHRNA5 expression based on histological grade with ER status. A) GSE3494 
studies B) GSE5460 studies C) GSE4922 studies with untreated samples D) GSE6532 studies 
with untreated samples. Grade 1 ER+ samples were assumed as control and equalized to 1. 
The fold change was calculated relative to Grade 1 ER+. * indicates p <0.0005 determined by 
student’s t-test. 
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4.2.2.3. Hormone therapy: 
 
 
In vitro studies show that estrogen induces the expression. In general, hormone therapy 
targets the ER receptors and reduces the estrogen- induced growth. So, tamoxifen treated and 
untreated samples from GSE6532 and endocrine therapy applied and not applied samples 
ER+ from GSE4922 samples were analyzed to examine this effect. In the Figure 4.2.13A, 
samples from GSE4922 datasets were ER+ this represents a homogenous population. 
Endocrine therapy decreased the expression in Grade 1 but did not affect the Grade 2 and 
Grade 3 patients (Figure 4.2.13A). In figure 4.2.13B, GSE6532 data sets were used. In 
GSE6532 dataset, although the ER status of patients was not unknown, ER- Grade 1 patients 
were very rare cases and the results in Figure 4.2.13B supported results in the Figure 4.2.13A 
that hormone therapy leads to reduction in expression of CHRNA5 in Grade 1 patients. 
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Figure 4.2.13. CHRNA5 expression based on therapy status with grade. A) GSE4922, all 
patients were ER+ and endocrine therapy was applied. B) GSE6532, the ER status of patients 
was unknown + and tamoxifen treatment was applied. * indicate p<0.05. 
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4.2.3. Analysis of Correlated Genes with CHRNA5: 
 
Previously, our study showed that CHRNA5 expression was altered by estrogen 
induction and was higher in ER negative and/or Grade 3 samples. These results led us to 
identify the correlated genes for further analysis. First, r>0.7 correlated probesets were 
defined in each in vitro data except GSE3529 and GSE11467. Then, the common probesets 
were determined, namely correlated genes (Table 4.2.4).  
 
Table 4.2.4. Correlated genes with CHRNA5. 
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To elucidate the function of correlated genes, GO and pathway analysis were 
performed via Webgstalt tool. Figure 4.2.14A shows that these genes function in regulation 
of progression in cell cycle, regulation of program cell death, DNA metabolism and 
regulation of apoptosis. In addition, they have DNA binding, purine nucleotide binding, 
enzyme binding and hydrolase activity (Fig. 4.2.14B) and KEGG pathway analysis (Table 
4.2.5) finds the cell cycle significant. Taken together, these results indicate that these genes 
may have role in cell cycle progression. 
 
Table 4.2.5. Pathway analysis of correlated genes with CHRNA5. 
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Figure 4.2.14. GO analysis of correlated genes. A) Biological Process level 6; B) Molecular 
Function level 4 .Writings in red color indicates p<0.05 according to Hyper Geometric Test. 
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Apart from the GO analysis, binary tree class prediction analysis with these genes was 
performed via BRB ArrayTool whether they can predict the different classes. Table 4.2.6 
showed the results of prediction according to ER status. ER+ and ER- samples were 
classified with an accuracy of about 80%. with these genes. Same analysis was performed to 
classify the samples according to grade status. Table 4.2.7 demonstrated that Grade 1 and 
Grade 3 samples were classified with accuracy of more than 75% with these genes but the 
classification of Grade 2 samples was changed from datasets. All these results suggest that 
the correlated genes may have role in cell cycle progression and have high prediction ability 
to discriminate the ER+ /ER- and Grade 1/Grade 3 samples. 
 
 
Table 4.2.6. Prediction analysis results for the correlated genes according to ER status. 
Binary Tree Prediction via K-nearest neighbor k=3 method, p<0.05. 
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Table 4.2.7. Prediction analysis results for the correlated genes according to histological 
grade. Binary Tree Prediction via K-nearest neighbor k=3 method, p<0.05. 
• G1:Grade 1; G2: Grade 2; G3: Grade 3.  
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CHAPTER 5: CONCLUSIONGS AND DISCUSSION 
 
5.1. Nicotine-mediated Signaling in MCF-7 Cells 
 
Tobacco use is one of the biggest threats to human health. Cigarette smoking is 
associated with close to 30% of all cancers; and for the lung, larynx and oral cancers this rate 
is much higher. On the other hand, smoking is considered as a risk factor for multiple other 
cancers, such as cancers of pancreas, liver, colon, and leukemia. Although nicotine is the 
most potent addictive and signal modulatory component in cigarette smoke, it has not been 
studied in detail in the context of breast cancers. Although it does not have carcinogenic 
activity, recent studies suggest that nicotine interacts with nAChRs and causes an increase in 
cell proliferation, tumor invasion and angiogenesis; in addition it has anti-apoptotic effects; 
thereby functions as a tumor enhancer (Egleton, Brown et al. 2008). Smoking as a risk factor 
for breast cancer is a controversial issue and only a few studies are present assessing the 
effects of nicotine in breast cancer cell lines, which have led us to study the effect of nicotine 
on breast cancer cells. 
In this study, nicotine-modulated gene expression in MCF7 breast carcinoma cell line 
was investigated. The subunits of α3, 5, 7, 9 and 10 and β1 and 4 nAChRs were found in 
MCF7 cells (data not shown) (Guo, Ibaragi et al. 2008). First, the proliferative activity of 
nicotine was examined under low and high serum concentrations. According to the MTT 
assay results, 2 days of 1 μM nicotine treatment in the presence or absence of serum was 
selected to assess the acute affect of nicotine in MCF7 cells. Second, since serum starvation 
potentially leads to cell cycle arrest and/or induces apoptosis, the effect of nicotine in MCF7 
cells were explored in terms of cell cycle process and apoptosis processes using molecular 
markers at the protein level. Finally, to assess the effect of nicotine on transcriptome in a 
genome-wide manner, microarray experiments were performed. Gene Ontology and pathway 
analyses were used to identify the functions of these nicotine-modulated genes. In addition, 
since nicotine exerts its biological activity via interaction with nAChRs, the effect of nicotine 
on nAChR expression also was explored in the context of serum responsiveness and response 
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to nicotine. Our findings established that the effects of nicotine on MCF7 cells were 
functionally extensive yet the changes in gene expression values were relatively mild. Serum 
depletion in the presence or absence of nicotine, on the other hand, resulted in drastic 
modulations in gene expression values, some of which could be reserved in the presence of 
nicotine after 2 days.  
Several studies show that nicotine accelerates the cell proliferation in normal and 
cancer cells (Gotti and Clementi 2004; Dasgupta, Rastogi et al. 2006; Schuller 2007). To 
explore the proliferative activity of nicotine in MCF7 cells, under physiological serum 
conditions, we assessed the dose- and time-dependency of nicotine exposure; cells were 
treated with different nicotine dose and for different time points; 0.1, 1 and 10 μM at 2, 3, 5 
and 7 days. The MTT results showed that nicotine at the selected doses and time periods did 
not induce the cell proliferation under physiological serum conditions. However, same dose 
of nicotine effectively rescued the loss of cell proliferation in the absence of serum starting 
from day 4 of the exposure. Guo et al. show that nicotine induces the cell proliferation in 
0.5% serum after 3 days exposure, thereby supporting our findings (Guo, Ibaragi et al. 2008). 
One of the outcomes of serum starvation is inhibition of the cell cycle progression. 
Serum starvation is known to decrease the levels of expression of cyclin D1 and cyclin E 
(Zerfass, Schulze et al. 1995; Kues, Anger et al. 2000; Cooper 2003; Demidenko and 
Blagosklonny 2008). In addition, kinases associated with cyclins D and E cause the 
hyperphosphorylation of RB and hyperphosphorylated RB dissociates from E2F, thereby 
leading to the activation of E2F-regulated proliferative promoters and facilitating the S-phase 
entry (Stevaux, Dimova et al. 2002). Therefore, the presence of cyclins D1 and E are 
essential for cell cycle progression. In the present study, we found that serum starvation led 
to a reduction in cyclin E levels and expectedly upon exposure to nicotine cyclin E protein 
levels increased. However, nicotine reduced the cyclin E levels under physiological serum 
conditions due to an unknown reason. Nevertheless, since this experiment was performed 
once, it should be repeated to come to a conclusion. 
Dasgupta et al. have shown that nicotine leads to resistance to chemotherapeutic drug 
induced-apoptosis. In addition, they have demonstrated that nicotine inhibits apoptosis via a 
reduction in p53 (Dasgupta, Kinkade et al. 2006). Herein, effects of 1 μM nicotine under 10% 
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serum or 0.1% serum conditions were studied at the level of Bcl-xl and p53. Serum starvation 
induced the expression of p53 while nicotine slightly decreased the p53 under serum 
starvation. No significant changes were observed under physiological serum conditions. 
Besides p53, nicotine induced the Bcl-xl expression at both serum levels though the increase 
in serum starvation was slightly higher than that in the untreated cell, as expectedly. These 
results suggest that proliferative and anti-apoptotic effects of nicotine was condition-
dependent, such that when the cell was insulted via reduction in growth factors, or increased 
stress such as lack of nutrients and/or DNA damage, nicotine-modulated pathways might 
likely to participate in restoring the cell’s proliferative capacity. 
In connection with the results of MTT assays and Western blots of cyclin E, Bcl-xl, and 
p53, the whole genome microarray results suggested that nicotine altered gene expression in 
subtle manners. Although a large number of genes became modulated within 2 days of 
exposure, the magnitude of alterations was low. This has been previously shown by several 
studies performed in the rat brain and PC12 cells, such that most genes with altered 
expressions did not go beyond 1.5 fold changes (Konu, Kane et al. 2001; Konu, Xu et al. 
2004). However, as shown previously, we have found that nicotine significantly influenced 
the diverse biological process such as regulation of cell adhesion, neuron differentiation, 
regulation of cell differentiation, vasculogenesis, cell death, cell growth, cell proliferation, 
regulation of metabolism, circadian rhytmn, and morphogenesis. In terms of Biocarta 
pathway analysis, regulation of MAP kinase pathways through dual specific phosphatases, 
IGF-1, EGF, and PDGF signaling pathways, caspase cascade in apoptosis, IL-6 signaling 
pathway, also were found to be significantly modulated. Focal adhesion, colorectal cancer, 
mTOR signaling pathways and nitrogen metabolism were identified according to the KEGG 
pathway analysis. In addition to alterations in cell growth and proliferation, alterations in 
growth factor signaling and dual specific phosphotases in the regulation of MAPK pathway 
suggested that nicotine may alter the cell proliferation of MCF7 cells. On the other hand, 
significant alterations in biological process, such as vasculogenesis, cell death and cell 
adhesion as well as caspase cascade activity, focal adhesion and colorectal cancer signaling 
pathways suggested that nicotine also might modulate the process of apoptosis, migration, 
and angiogenesis. Taken together, all these results support the notion that nicotine alters the 
proliferative, angiogenetic, migration, and apoptotic processes of the cells (Egleton, Brown et 
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al. 2008). Future studies are needed to show which of these processes and through what 
mechanisms are modulated using studies focusing on phosphorylation status of the effector 
proteins. 
Several studies showed that nicotine leads to resistance against apoptosis induced by 
extracellular stress stimuli such as opioids, UV radiation, Ca++ ionophores, neurotoxins, oxi-
dative stress and anticancer drugs and induce survival in lung cancer, oral cancer, and head 
and neck cancer cells (Dasgupta, Kinkade et al. 2006; Zeidler, Albermann et al. 2007). 
Therefore, herein, we provide preliminary information that starvation-induced stress (Cooper, 
Hutchison et al. 2003) increased nicotine-induced modulation of gene expression when 
compared with physiological serum conditions. According to GO analysis, differentially 
expressed genes were involved in different kind of biological processes: notch signaling, 
protein kinase pathway, stress activated protein kinase signaling pathway, positive regulation 
of signal transduction, regulation of IκB kinase/NFκB cascade, apoptosis, regulation of 
program cell death and negative regulation of progression through cell cycle. Caspase 
cascade in apoptosis, role of mitochondria in apoptotic signaling, regulation of BAD 
phosphorylation, ceramide signaling pathway (Shirakabe, Yamaguchi et al. 1997) found by 
Biocarta pathway analysis, and apoptosis identified by KEGG pathway analysis 
demonstrated that serum starvation might have induced the apoptotic signaling and nicotine 
significantly altered a subset of these pathways. On the other hand, findings of the regulation 
of I-κ B kinase/NFκB cascade and MAPK pathway identified by KEGG pathway analysis 
suggest that nicotine might play key roles in cell proliferation as well as cell death (Santen, 
Song et al. 2002). Apart from these pathways, focal adhesion, tight junctions (Sawada, 
Murata et al. 2003), and VEGF signaling pathways significantly altered by nicotine suggest 
roles for nicotine in cell migration (Yamamura, Amano et al. 1998; Cross and Claesson-
Welsh 2001; Wozniak, Modzelewska et al. 2004). Thus, these results also support the recent 
studies (Guo, Ibaragi et al. 2008; Dasgupta, Rizwani et al. 2009) implicating nicotine as an 
inducer of cell migration in MCF7 cells. 
Since nicotine have restored the level of cell proliferation back to normal levels at day 5 
or later when treated with no serum, it was important to examine what serum depletion has 
done to MCF7 cells. However our analyses have focused on effects of nicotine and serum at 
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day 2, at which cell proliferation was not seemingly affected either in the absence or presence 
of nicotine. It is possible that our results showing transcriptional changes in the direction 
closer to 10% serum level transcriptome might represent a small modulation towards the 
protective effects of nicotine. In the light of these, GO analysis demonstrated that this gene 
set functioned in protein kinase pathway, stress activated protein kinase signaling pathway, 
positive regulation of signal transduction, regulation of IκB kinase/ NFκB cascade, apoptosis, 
regulation of program cell death, and negative regulation of progression through cell cycle. 
Similar to previous analysis, caspase cascade in apoptosis, role of mitochondria in apoptotic 
signaling, ceramide pathway and regulation of BAD phosphorylation from biocarta pathway 
analysis are found significant. These results suggested that nicotine might alter the apoptotic 
pathway and might prepare cells for recovery from serum-starvation induced stress. A greater 
number of probesets changed in the direction of 10 % serum than opposite to 10% serum 
transcriptome suggesting that nicotine might induce mild changes in the opposite direction of 
serum starvation. In other words, for instance, when gene expression was higher under 10% 
serum conditions, serum starvation led to a decrease but nicotine treatment under serum 
starvation conditions led to either an increase reversing the effect of starvation. However, 
these findings depended on a single replicate and thus were represented as fold changes. The 
statistical significance of these fold changes should be confirmed using multiple replicates 
from the Day2 serum starvation experiments. Furthermore, there might be differences 
between Day2 and Day5, at which the effects of nicotine was more pronounced, therefore 
expression profiling will be extended to Day5 to better understand the magnitude of 
alterations and ability of nicotine to counteract changes taking place during serum starvation. 
nAChR genes are likely to act in concert because they exist in pentamer combinations. 
One possibility is that these genes also have similar expression patterns because of common 
transcriptional regulation, at least for subsets of receptor subunits. Our findings indicated that 
indeed they behaved similarly, yet the expression levels may not be significantly altered in 
the presence of nicotine, although statistical tests are needed at the point upon increasing 
sample size of the experiments. Yet a few of the subunits were highly responsive to lack of 
serum. This suggested that serum depletion represented a modulator for the nAChR 
signaling; nicotine in a dose dependent manner may or may not change the levels of these 
subunits. The time period studied here was 2 days, which may not be adequate for the effects 
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on cell proliferation and apoptosis to completely show up. In fact, we have demonstrated that 
at days 5 and 7, nicotine at even low concentrations was able to lead to an increase in cell 
proliferation at 0.1% serum. The change in CHRNA4 expression was the most striking 
finding although the level of modulation is less than the cut-off value, it was highly 
significant. Since the heteromeric α4β2nAChR has a major inhibitory activity in cancer 
development and progression (Schuller 2009), this decrease suggested that nicotine may have 
role in cancer development via modulating the α4nAChR expression. 
Since all changes reported in cholinergic receptors at the 0.1% serum levels represent 
fold changes they have to be repeated using other microarray experiments and should be 
confirmed using real-time RT-PCR measurements. However, CHRNA5, CHRNA10 and 
CHRNB1 genes seemed to be modulated by serum to a greater extent. In addition, the 
decrease in CHRNA5 was more than 2 fold. Since estrogen is one of the ingredients of the 
fetal bovine serum and have a key role in breast cancer development, it is likely that nicotine-
modulated signaling cross-talks with estrogen modulated pathways. This finding together 
with accumulating information on the polymorphism studies performed on CHRNA5 
recently have lead us to examine the estrogen treated breast cancer cell microarray datasets 
with respect to CHRNA5 expression modulation, as presented in later in the results. 
In summary, our data showed that nicotine behaved differently under different serum 
conditions and nicotine altered the multiple biological process in MCF7 cells including, cell 
growth, apoptosis, cell proliferation, vasculogenesis. The abnormality of these biological 
processes lead to the development and progression of cancer so our results supported the idea 
that nicotine might carry a tumor-enhancer activity. 
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5.2. Involvement of Estrogen in CHRNA5 mRNA expression: 
 
According to the American Cancer Society 2009 report, breast cancer is the most 
frequently diagnosed cancer in women except the skin cancer (ACS 2009). Estrogen 
hormone is strongly associated with the development and progression of the breast cancer 
(Anderson 2002). Therefore, several studies have been performed to elucidate the estrogen 
mechanisms in breast cancer. Since understanding of histological features and molecular 
alterations in breast cancer is essential to find novel therapeutic approaches with higher 
success in curing the disease, ER and histological grade status are some of factors to classify 
the breast cancers. On the other hand, recent studies demonstrate the association of CHRNA5 
with nicotine dependence and lung cancer risk (Falvella, Galvan et al. 2009; Wang, Cruchaga 
et al. 2009). In addition, our gene expression analysis of nAChRs under different serum 
conditions shows that serum starvation might reduce CHRNA5 expression. Estrogen is one 
of the ingredients of serum suggesting that CHRNA5 might be regulated in a growth factor 
dependent manner. Evidently, all these reasons lead us to re-analyze microarray data related 
to estrogen treatment and ER. 
In this study, our analysis implicated that estrogen induced the expression of CHRNA5. 
This induction was dose-dependent at lower doses and time-dependent in short-time 
exposure. In addition, CHRNA5 has been identified as a possible secondary target of 
estrogen signaling. Estrogen-independent and anti-estrogen resistant cells had higher level of 
CHRNA5 expression. According to primary tumor studies, higher level of CHRNA5 
expression was observed in ER- patients. Therefore, estrogen might regulate the CHRNA5 
expression and its deprivation eventually may lead to higher expression. Primary tumor 
studies showed that Grade 3 tumors have higher CHRNA5 expression and hormone therapy 
led to reduction in expression in Grade 1. Correlated genes functioning in cell cycle with high 
predictive ability indicated that a high level of CHRNA5 expression may be associated with 
Grade 3 since high mitotic activity also correlated with Grade 3 (Baak, Van Dop et al. 1985). 
Interestingly, estrogen did not induce the expression of CHRNA5 in BT-474 cell line 
(GSE3529). Wang et al. found that BT-474 was ER positive yet tamoxifen resistant cell line 
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(Wang, Yang et al. 2006). Therefore, these supported the results of OHT-resistant MCF7 
cells (GSE5840) in which CHRNA5 expression did not change in response to estrogen in 
tamoxifen-resistant cells. 
 Nakazawa and Ohno showed that estrogen and phyto-oestrogens led to desensitization 
of α4β2nAChR by unknown mechanisms (Nakazawa and Ohno 2001). Our results show the 
increase in the expression of CHRNA5 in response to estrogen. Indeed, the inclusion of 
CHRNA5 subunit in α4β2 may lead to desensitization (Ramirez-Latorre, Yu et al. 1996). 
Thus, estrogen may lead to desensitization of α4β2nAChR via increasing the CHRNA5 
expression. 
Hyperactive GFR and MAPK signaling is one of the reasons for the ER loss and 
hormone therapy resistance in breast cancer (Holloway, Murthy et al. 2004; Creighton, 
Cordero et al. 2006; Bayliss, Hilger et al. 2007; Lopez-Tarruella and Schiff 2007). Our 
analysis indicated that CHRNA5 expression was higher in ER- patients and anti-estrogen 
resistant MCF7 cells. Since it is known that the inclusion of CHRNA5 subunit in α3β4 or 
α3β2 receptors may lead to functional changes including increased Ca++ permeability 
(Gerzanich, Wang et al. 1998) it would be likely that higher expression of CHRNA5 may 
lead to increased MAPK activity thereby, leading to hormone-resistancy and ER loss. 
Our microarray meta-analysis studies provided valuable information about the 
association of CHRNA5 with breast cancer; further molecular and functional analyses should 
be performed to elucidate the mechanisms of CHNRA5 in breast cancer. 
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5.3. Future Perspectives: 
 
In the present study, we have demonstrated that nicotine at 1uuM concentrations affects 
cell proliferation in a dose and time dependent manner using MTT assays, and molecular 
markers. Future studies will focus on understanding the nature of these proliferative effects. 
We will investigate the change of expression at the protein level using known proliferative 
and apoptotic markers. Furthermore, apoptosis assays will be used to detect whether the 
reduction in proliferation is due to growth arrest and/or apoptosis. These studies will be 
performed in a dose- and time-dependent manner. 
The microarray experiments analyzed herein are preliminary since they included 1-2 
replicates of each group. Studies are on going to increase the number of replications as well 
as to extend the expression profiling to Day 5 of serum starvation, at which the effects of 
nicotine were more prominent based on the MTT assay. Pathway analysis tools, such as 
Pathway Miner will also be used to identify networks, consistently modulated at Day 2 and 
Day 5 of serum starvation. Futhermore, a time course study of nicotine exposure at 10% 
serum levels also will be analyzed together with the serum data to understand consistent 
patterns of expression changes.  
It is well known that nicotine exerts its proliferative activity via Ras and its downstream 
effector Raf/MAP kinase activity (Egleton, Brown et al. 2008). Chu et al. indicate that long-
term nicotine exposure in mouse epithelial cells increases the RAS activity and RAF1 
translocation to the plasma membrane despite no changes could be observed in expression 
(Chu, Guo et al. 2005). In another study, nicotine enhances the kinase activity associated with 
cyclins D and E thereby, leading to progression of cell cycle (Dasgupta, Rastogi et al. 2006) 
Taken together, nicotine accelerates the cell proliferation via activating on different kinases. 
MAPK pathways, found to be significantly modulated in our study might, provide a link to 
the kinase activity induced by nicotine. The genes affected by nicotine and role in MAPK 
pathway will be studied upon exposure to kinase inhibitors to elucidate better the 
proliferative activity of nicotine on MCF7 cells. 
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Apart from the proliferative activity, nicotine induces the PI3K/AKT pathway, 
PKC/RAF/MEK/ERK1 pathway or PKA and leads to phosphorylation of anti-apoptotic 
protein bcl-2, pro-apoptotic proteins bad and bax and might protect cells from going through 
apoptosis. Therefore, performing the experiments with these antibodies may give better 
results about the effects of nicotine on apoptosis. On the other hand, GO and pathway 
analysis showed that nicotine altered the caspase cascade activity. Thus, caspase assays will 
be essential to illuminate the effect of nicotine in MCF7 cells under serum starvation 
conditions. 
Recent studies show nicotine affects migration in MCF7 cells (Guo, Ibaragi et al. 2008; 
Dasgupta, Rizwani et al. 2009). We identified candidate genes involved in vasculogenesis, 
focal adhesion, tight junction, and VEGF signaling pathways that are essential for cell 
migration and metastatic process. Consequently, the metastatic effect of nicotine in MCF7 
might be studied in the future by modulating levels of expression of these genes through 
overexpression or siRNA applications. 
In both 10% serum and 0.1% serum experiments, nicotine altered the gene expression 
no more than 2.0 fold. Cells were treated with nicotine only for 2 days. In addition, our study 
and Guo et al. demonstrated that the proliferative effect of nicotine took place after 3 days 
(Guo, Ibaragi et al. 2008). Furthermore, MCF7 cells were maintained in DMEM medium 
supplemented with 10% serum, 1% non-essential and 1% penicillin/streptomycin. Before 
nicotine treatment, the cells were starved for 24 hr to minimize the heterogeneity caused by 
the effects of growth factors and to obtain the synchronized cells. However, MCF7 cell line is 
ER+ and estrogen leads to cell proliferation in this cell line. In addition, the estrogenic 
activity of phenol red medium is well-known. Therefore, using phenol red medium might 
have decreased the efficiency of our experiments. To sum up, cells grown in phenol-red free 
media and longer exposure times to nicotine may lead to higher expression differences and 
might give better resolution with respect to effects of nicotine on MCF7 cell proliferation and 
apoptosis mechanisms. 
Our study identified CHRNA5 as a target of estrogen signaling based on in vitro and in 
vivo microarray studies. These studies can be extended and confirmed with an independent 
set of breast tumors of different molecular subtypes using RT-PCR and antibodies. 
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Furthermore, microarray studies can be extended to those with data on prognosis of the 
patients. 
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 CHAPTER 6. APPENDICES 
 
APPENDIX A: Positive control of estrogen studies 
 
 
Figure 6.1. pS2 expression A) In GSE4668 (Coser, Chesnes et al. 2003), MCF7/BUS cells 
were treated with E2 different doses for 48 h. B) In GSE4668 (Coser, Chesnes et al. 2003), 
MCF7/BUS cells were grown in hormone-starved medium for 0, 1 or 2 day. C) In GSE11324 
(Carroll, Meyer et al. 2006), MCF7 cells were treated with 100 nM E2 for 0, 3, 6 or 12 h. D) 
In GSE11352 (Lin, Vega et al. 2007), MCF7 cells were treated with/without 10 nM for 12, 
24 or 48 h. * indicates p<0.05 determined by student’s t-test, compared with untreated 
samples. sP2 probeset: 205009_at. 
134 
 
 
Figure 6.2. MYC and E2F1 expression in response to E2 in the presence or absence of 
cycloheximide. In GSE8597 (Bourdeau, Deschenes et al. 2008), MCF7 cells were treated 
with 25 nM E2 in the presence / absence of cycloheximide for 24 h. A) MYC expression in 
response to E2 with/without cycloheximide, MYC is the primary target of E2 (Bourdeau, 
Deschenes et al. 2008) B) E2F1 expression in response to E2 with/without cycloheximide, 
E2F1 is the secondary target of E2 (Bourdeau, Deschenes et al. 2008). * indicates p<0.005 
determined by student’s t-test. MYC probeset: 202431_s_at; E2F1 average of probesets: 
2028_s_at and 204947_at.
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Figure 6.3. MYC and E2F1 expression in response to E2 for 2 h. In GSE11467(Frasor 2008), 
MCF7 cells were treated with 10 nM E2 for 2 h. A) MYC expression in response to E2. B) 
E2F1 expression in response to E2. * indicates p<0.07 determined by student’s t-test. MYC 
probeset: 202431_s_at; E2F1 average of probesets: 2028_s_at and 204947_at. 
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